1	RIPK1 Biallelic Activating Variants lead to Autoinflammatory Disease Driven by T cell Death			
2				
3	Jialin Dai ^{1,3,11} , Taijie Jin ^{2,3,11} , Gaixiu Su ^{4,11} , Xu Han ³ , Jun Wang ³ , Chenlu Liu ³ , Wenjie Zheng ⁵ , Qiuye			
4	Zhang ⁶ , Jun Yang ⁷ , Li Guo ⁸ , Dan Zhang ⁴ , Ming Li ⁴ , Yingjie Xu ⁴ , Tong Yue ⁴ , Min Wen ⁴ , Jia Zhu ⁴ , Min			
5	Kang ⁴ , Jianming Lai ⁴ , Feifei Wu ⁴ , Shihao Wang ³ , Jiahui Zhang ³ , Pui Y. Lee ⁹ , Junying Yuan ^{10*} , Xiaomin			
6	Yu ^{1,2*} , Qing Zhou ^{1,3*}			
7				
8	1 Liangzhu Laboratory of Zhejiang University, and Department of Rheumatology, Sir Run Run Shaw			
9	Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China			
10	2 Department of Rheumatology, The Second Affiliated Hospital, Zhejiang University School of Medicine,			
11	Hangzhou, Zhejiang, China			
12	3 Life Sciences Institute, Zhejiang University, Hangzhou, Zhejiang, China			
13	4 Department of Rheumatology and Immunology, Capital Institute of Pediatrics, Beijing, China			
14	5 The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University,			
15	Wenzhou, Zhejiang, China			
16	6 Department of Pediatric Nephrology, Rheumatology and Immunity, The Affiliated Hospital of Qingdao			
17	University, Qingdao, China			
18	7 Department of Rheumatology and Immunology, Shenzhen Children's hospital, Shenzhen, China			
19	8 Department of Rheumatology Immunology & Allergy, Children's Hospital, Zhejiang University School			
20	of Medicine, Hangzhou			
21	9 Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA			
22	10 Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry,			
23	Chinese Academy of Sciences, Shanghai, China			
24	11 These authors contributed equally: Jialin Dai, Taijie Jin, Gaixiu Su.			
25	*These authors jointly supervised this work: Qing Zhou, Xiaomin Yu, Junying Yuan.			
26				
27	Corresponding authors			
28	*E-mail: zhouqingnwu@gmail.com; yuxiaomin78@gmail.com; junying_yuan@sioc.ac.cn.			
29				
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 30				

31 Abstract

32 Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) is a key regulator of cell fate decision 33 between pro-survival signaling and programmed cell death. The activation of RIPK1 is extensively 34 modulated by posttranslational modification, such as ubiquitination. RIPK1 overactivation mediates 35 autoinflammatory diseases in humans. However, the role of RIPK1 ubiquitination in human 36 autoinflammatory diseases has not been reported, and the mechanism mediating the interaction of cell 37 death and autoinflammation is largely unknown. Here, we report two patients carrying compound 38 heterozygous *RIPK1* variants K377E/R390G with recurrent fevers, lymphadenopathy and skin rashes. 39 Mechanistically, K377E and R390G mutations impaired ubiquitination of RIPK1, which suppresses the 40 formation of TNFR1 signaling complex (TNF-RSC) and NF-kB activation, resulting in the loss of CD8+ 41 T cells mediated by RIPK1 activation-induced cell death in the patients. We reveal that the death of CD8⁺ 42 T cells promotes the secretion of TNF and IFNy to activate monocytes and macrophages, which triggers 43 further production of proinflammatory cytokines to amplify autoinflammation. Disruption of the 44 communication between T cells and monocytes/macrophages through pharmacologic blockade of TNF 45 and IFNy attenuated proinflammatory cytokine production in macrophages. Collectively, our results 46 demonstrate a crucial role of RIPK1 ubiquitination in regulating CD8⁺ T cell death and restraining 47 autoinflammation. Our study demonstrates the mechanism for a group of autoinflammatory diseases 48 mediated by RIPK1 activation-induced cell death, and highlights an important role of CD8⁺ T cells in 49 driving autoinflammation.

50 Introduction

51 Systemic autoinflammatory diseases (SAIDs) are a group of disorders induced by overactivation of 52 innate immune system characterized by recurrent fever and multi-organ inflammation, but typically 53 without high-titer antibodies or antigen-specific T cells. Distinct from autoimmune diseases defined by 54 dysregulation of the adaptive immune system, SAIDs are believed to be mostly driven by the malfunction 55 of innate immune cells such as monocytes and neutrophils ^{1,2}. Therefore, the contribution of adaptive 56 immune cells in triggering activation of myeloid cells has not been appreciated in the pathogenesis of 57 SAIDs.

58 To date, more than 50 genes responsible for monogenic SAIDs have been identified. The list of 59 genes whose mutations lead to SAIDs are enriched with key regulators of programmed cell death (PCD). 60 Enhanced PCD is one of the characteristics in the SAID patients caused by the cleavage resistance 61 mutations in RIPK1³⁻⁵ or deficiencies of RIPK1^{6,7}, TANK-binding kinase 1 (TBK1)⁸, OTU deubiquitinase 62 with linear linkage specificity (OTULIN), HOIL1-interacting protein (HOIP), Heme-oxidized IRP2 63 ubiquitin ligase-1 (HOIL1) and Shank-associated RH domain-interacting protein (SHARPIN)⁹. 64 Pathogenic variants of these genes have been shown to activate apoptosis and necroptosis in cellular or 65 murine models¹⁰. While excessive cell death is strongly linked to autoinflammatory diseases in humans, 66 the mechanism by which cell death causes spontaneous inflammation in these conditions is unknown.

67 RIPK1 is a key mediator of cell death and inflammation¹¹. Overactivation of RIPK1 leads to 68 enhanced apoptosis, necroptosis and inflammatory response in mice and humans¹². Whereas *RIPK1* 69 deficiency and heterozygous non-cleavable variants in *RIPK1* cause immunodeficiency and dominantly 70 inherited autoinflammatory diseases, respectively, a recessive autoinflammatory disease caused by 71 RIPK1 variants has not been reported. K63-linked ubiquitination of RIPK1 on K377 is essential for NF- κ B pathway activation and negative regulation of cell death. Mice bearing *Ripk1*^{K376R/K376R} knockin 72 73 mutation displays embryonic lethality due to excessive apoptosis and necroptosis caused by RIPK1 74 activation¹³⁻¹⁵. Ablation of *Fadd* and *Mlkl/Ripk3* rescues the embryonic lethality and allows them to grow 75 into fertile adults. Nevertheless, the function of RIPK1 ubiquitination in human disease has not been 76 defined and studied. In this study, we identified two autoinflammatory patients carrying recessively 77 inherited compound heterozygous RIPK1 variants K377E/R390G. We demonstrate that RIPK1 78 K377E/R390G variants lead to autoinflammatory disease by prompting RIPK1 activation-mediated the 79 death of CD8⁺ T cells.

80 Results

81 Biallelic *RIPK1* mutations in patients with autoinflammation

82 We identified two children from one family with autoinflammatory disease characterized by recurrent 83 fevers, lymphadenopathy and skin rashes (Fig. 1a-d). The proband (Patient 1, P1) exhibited very early 84 onset inflammatory bowel disease (VEO-IBD) characterized by diarrhea, abdominal pain and perianal 85 abscess. At the age between 0-5, respectively, P1 and patient 2 (P2) displayed fever episodes that last 3-86 4 days and recurred every 8-9 days. Their fever episodes were accompanied by elevated serum C-reactive 87 protein (CRP), serum amyloid A (SAA), erythrocyte sedimentation rate (ESR), D-dimer and lactate 88 dehydrogenase (LDH) (Fig. 1e, Extended Data Fig. 1a-c). Neither case exhibited evidence of 89 immunodeficiency or infection. In addition, the levels of pro-inflammatory cytokines IL-6 and TNF were 90 strongly increased in the serum of both patients during flares (Fig. 1f). Serum CRP levels and adenosine 91 deaminase (ADA) activity in patients were higher than that of unaffected controls and parents during 92 disease flares and even in remission (Fig. 1f). P1 had taken prednisone during flares, with resolution of 93 fever but limited effect on inflammatory indexes (Fig. 1e, Extended Data Fig. 1a-c).

94 By performing whole exome sequencing (WES) and sanger sequencing on the family, we identified 95 that both P1 and P2 carried the *RIPK1* compound heterozygous mutations (c. 1129A>G / p. K377E and 96 c. 1168C>G / p. R390G), whereas their unaffected mother and father were heterozygous carriers of 97 RIPK1 R390G and K377E, respectively (Fig. 1g, Extended Data Fig. 1d-e). Therefore, this 98 autoinflammatory disease in the siblings appeared to be recessively inherited and segregated with the 99 inheritance of both RIPK1 variants. The lysine residue at amino acid position 377 is the site for K63-100 linked ubiquitination of RIPK1¹⁶, while the function of residue R390 has not been characterized. Both 101 K377 and R390 residues are conserved in RIPK1 across species (Fig. 1h). The two RIPK1 variants were 102 predicted to be deleterious with their CADD scores well above that of the non-cleavable RIPK1 103 mutations D324V, D324H and D324N (Extended Data Fig. 1f).

104

RIPK1 activating mutations impair ubiquitination of RIPK1 and NF-κB activation and promote cell death

- Given that RIPK1 is a widely expressed regulator of pro-survival NF-κB signaling and programmed cell
 death, we utilized SV40-immortalized human dermal fibroblasts (SV40-HDFs) derived from unaffected
- 109 controls and P2 to assess the functional status of these signaling pathways. SV40-HDFs from P2 show

increased sensitivity to apoptosis induced by TNF (T) with cIAP1/2 degrader SM-164 (S) as well as
necroptosis induced by TNF (T) with pan-caspase inhibitor z-VAD-FMK (Z) or TSZ (Fig. 1i, Extended
Data Fig. 2a), and enhanced RIPK1 activation as shown by phosphorylation at S166 and that of MLKL
as shown by phosphorylation at S358, which were rescued by the RIPK1 kinase inhibitor Necrostatin-1s
(Nec-1s) (Fig. 1j, Extended Data Fig. 2a). These results suggest that the compound R390G and K377E
mutations in RIPK1 promote the activation of RIPK1.

116 TNF-RSC is an important signaling complex that forms within minutes upon TNFR1 activation by 117 TNF¹⁷. We next determined the effect of R390G and K377E compound mutations on TNF-RSC 118 formation in SV40-HDFs upon stimulation with Flag-TNF. Ubiquitination of RIPK1 as well as 119 recruitment of NEMO, IKK β and SHARPIN to the TNF-RSC were impaired in P2 SV40-HDFs 120 compared to unaffected controls (Fig. 1k). Furthermore, the activation of NF- κ B and MAPK signaling 121 by TNF were impaired in P2 SV40-HDFs as revealed by reduced phosphorylation of IKK α/β , p65, I κ B α , 122 ERK and JNK (Fig. 11).

123 The above findings were further investigated in RIPK1-/- HT-29 cell lines complemented with wild-124 type (WT), K377E and R390G RIPK1, K377E and R390G compound mutations sensitized HT-29 cells 125 to RIPK1-dependent cell death (Extended Data Fig. 2b-c). Furthermore, RIPK1-/- HT-29 cells expressed 126 K377E or R390G RIPK1 alone were also sensitized to TS and TSZ stimulation induced cell death to the 127 same extent as that express both K377E and R390G (Fig. 1m-n, Extended Data Fig. 2d). Thus, K377E 128 and R390G compound mutations or single mutation alone can promote cell death. Notably, the 129 expression of K377E and R390G compound mutations or individual K377E and R390G mutation alone 130 also reduced the levels of RIPK1 ubiquitination in TNF-RSC (Fig. 10), as well as the activation of NF-

131 κB and MAPK (Fig. 1p), and the production of downstream cytokines (Extended Data Fig. 2e).

K377 is a ubiquitination site in RIPK1 intermediate domain (ID domain)¹⁶. Consistently, K377E, but not 132 133 R390G, directly abolished the ubiquitination of ID domain (Extended Data Fig. 2f). Since R390 is not 134 expected to be the site of ubiquitination, we considered the possibility that R390G might affect the 135 recruitment of E3 ubiquitination complexes. Mind Bomb-2 (MIB2) is known to be an E3 ubiquitin ligase 136 recruited to TNF-RSC to mediate RIPK1 ubiquitination¹⁸. We found that the interaction between Mind 137 Bomb-2 (MIB2) and RIPK1 R390G was demonstrated to be significantly reduced, which partly 138 explained for the impaired ubiquitination of R390G RIPK1 (Extended Data Fig. 2g). Collectively, these 139 data demonstrate that both K377E and R390G mutations promote RIPK1 activation-dependent cell death

140 and impaired pro-survival NF-κB signaling by modulating RIPK1 ubiquitination in TNF-RSC.

141

142 Activation of inflammatory signaling in myeloid cells of the patients

143 We next studied the inflammatory signaling pathways by performing single-cell RNA sequencing on 144 peripheral blood mononuclear cells (PBMCs) from P1, P2 and three unaffected controls. The monocyte 145 compartment in patients was significant expanded (Fig. 2a, Extended Data Fig. 3a). Similar to the 146 previously reported *RIPK1* D324V mutant⁴, transcriptional up-regulation of proinflammatory cytokines 147 (IL1B and CXCL8) was detected in patient cells, especially in monocyte subsets (Fig. 2b). Likewise, 148 differential gene expression analysis revealed greatest up-regulation of genes governed by NF-kB and 149 type-I IFN pathways in myeloid cells from the patients (Fig. 2c-d, Extended Data Fig. 3b-c). The up-150 regulated genes in the patients' monocytes were also enriched for pathways of cytokine production, 151 cytokine stimulation, and negative regulation of cell death in the gene ontology (GO) analysis (Fig. 2e, 152 Extended Data Fig. 3d), suggesting that myeloid cells play a crucial role in increased cytokine production 153 and pro-inflammatory signal transduction in the patients. Increased basal expression of IL-1 β , IL-6 as 154 well as IFNy in monocytes from P1 was confirmed by flow cytometry (Fig. 2f). However, monocytes 155 isolated from the patients exhibited reduced transcription of NF-κB regulated genes including *IL1B*, *IL6*, 156 CXCL8 and TNF in response to TNF stimulation (Fig. 2g), in accordance with suppressed NF-κB 157 activation in SV40-HDFs as demonstrated earlier (Fig. 1k, l). Thus, the increased inflammatory response 158 of myeloid cells in the patients was likely represented a secondary effect triggered by K377E/R390G 159 variants.

160 As RIPK1 overactivation can promote programmed cell death leading to inflammation¹⁹, we 161 assessed the cell death response of monocytes to TNF stimulation. The monocytes from the patients were 162 more sensitive to TS-induced apoptosis than that of unaffected controls, whereas they showed similar 163 sensitivity to necroptosis induced by TSZ (Fig. 2h). In addition, no differences of apoptosis and 164 necroptosis were observed between monocyte-derived macrophages (MDMs) from patients and that 165 from unaffected controls (Fig. 2i, Extended Data Fig. 3e). On the other hand, although the expression of 166 cell death suppressor genes TNFAIP3, BCL2A1, BCL6, BCL3, RNF144B, BIRC2 and BIRC3 were 167 elevated in patients' various immune cell types, monocytes, LDG and DC cells express these genes 168 significantly higher than that in lymphocyte subsets (Fig. 2j, k and Extended Data Fig. 3f). These results 169 suggest that the elevated inflammatory response of monocytes induced by K377E/R390G variants may

170 be regulated non-autonomously by other cell types that were more susceptible to cell death.

171 To define the upstream factors that drove the overproduction of inflammatory cytokines in 172 monocytes, we employed semi-quantitative protein microarray analysis on serum samples from 173 unaffected controls and P2 (Fig. 21-m). We collected samples before and after the first fever episode 174 (disease onset) for P2. Differentially expressed cytokines were clustered into three groups according to 175 the data trend. Twenty-eight cytokines in group 1 (such as IL-1 β) peaked during flare, reflecting a direct 176 correlation with fever status (Fig. 2n, Extended Data Fig. 4a-b). 24 cytokines in group 2 (such as sCD95) 177 (Fig. 2n, Extended Data Fig. 4c-d) and 32 cytokines in group 3 (Extended Data Fig. 4e-f) continuously 178 changed across samples of P2. Up-regulated cytokines in group 2 were considered to be directly regulated 179 by the RIPK1 K377E/R390G mutations.

180 To further define the source of the cytokines in group 1 and 2, we compared the expression scores 181 of the two groups between patients and unaffected controls by analyzing single cell RNA-seq data. The 182 cytokines in group 1 were most significantly up-regulated in patients' monocytes, low-density 183 granulocyte (LDG), plasmacytoid dendritic cell (pDC) and plasma cells (Fig. 20), consistent with the 184 strong inflammatory signature in myeloid cells during fever. Notably, the genes encoding cytokines in 185 group 2 were up-regulated most significantly in the patients' lymphocyte subsets, especially in CD8⁺ T 186 cells (Fig. 20), implying a pathogenic role of K377E/R390G variants in T lymphocytes. In addition, the 187 expression levels of cell death suppressor genes in T lymphocytes were also lower compared with 188 monocytes, LDG, pDC and plasma cells (Extended Data Fig. 3f), suggesting that T lymphocytes may be 189 sensitized to undergo programmed cell death. Collectively, these results supported a critical role of 190 monocytes in promoting inflammation and implied that T lymphocyte subsets may also contribute to the 191 pathophysiology of this autoinflammatory disease.

192

193 RIPK1 activation leads to increased cell death and CD4/CD8 ratio in T cells

To better understand the impact of *RIPK1* mutations on immune profile, we performed cytometry by time-of-flight (CyTOF) on PBMCs isolated from unaffected controls and patients. CyTOF result revealed that CD4⁺T, B and $\gamma\delta$ T cell proportions in patients were elevated whereas CD8⁺ T and NK cell proportions were reduced comparing to unaffected controls (Extended Data Fig. 5a-b). Apoptosis indicated by cleaved caspase-3 was increased in CD8⁺ TEMRA, $\gamma\delta$ T, NK and B cell subsets of patients (Fig. 3a). Flow cytometric analysis confirmed that patients' CD4⁺ and CD8⁺ T cells, not CD19⁺ B cells

200 and CD14⁺ monocytes, displayed augmented activation of RIPK1 and cleaved caspase-3 (Fig. 3b-e, 201 Extended Data Fig. 5c-f). Furthermore, CD3⁺ T cells isolated from patients were more sensitive to TS-202 induced apoptosis and TSZ-induced necroptosis. They displayed higher levels of RIPK1 phosphorylation 203 at S166 and MLKL phosphorylation at S358 comparing to that of unaffected controls, and these patterns 204 were inhibited by treatment with Nec-1s (Fig. 3f-g), indicating that T cells bearing K377E/R390G 205 mutations were more prone to RIPK1-dependent cell death. In accordance with the recessive inheritance, 206 no significant differences of cell death were observed between unaffected parents carrying heterozygous 207 mutation and unaffected controls.

208 The CyTOF results also revealed a global activation of patients' immune cells as indicated by CD69 209 expression, while elevated CD38 expression appeared to be restricted to B cells and T cells (Extended 210 Data Fig. 5g-h). Increased expression of CD69 in T cells was further validated by flow cytometry (Fig. 211 3h). Concomitantly, higher levels of T cell activation-related proinflammatory mediators including 212 sCD25, TNF and IFNy were observed in the serum of P1 and P2 as well as (cleavage-resistant RIPK1-213 induced autoinflammatory) CRIA patients (Fig. 3i). Activated lymphocytes undergo cell expansion and 214 indeed we observed an elevation in the number of total lymphocytes, as well as that of CD3⁺ T cells, 215 $CD4^+$ T cells and B cells, except for that of cytotoxic $CD8^+$ T cells and NKT cells in the 216 immunophenotyping results (Fig. 3j, Extended Data Fig. 6a). As a consequence of the loss of CD8⁺ T 217 cells, CD4/CD8 ratio was significantly increased in patients. In vitro expansion of T cells isolated from 218 patients upon anti-CD3/CD28 stimulation were abnormal, but the proliferation ability was undampened 219 (Fig. 3k-l), reflecting the occurrence of T cell death. Specifically, CD8⁺ T cells went through a contraction 220 phase after activation presumably resulted from activation-induced cell death (AICD)²⁰. The augmented 221 signal of CD95 (Fas) on the surface of patients' T cells accompanied by elevations of serum sCD95 and 222 CD95L levels also supported increased AICD (Fig. 3i, m).

To further characterize the abnormalities in the patient T cells, we analyzed T cell subsets from *in vitro* cultured PBMCs. We observed that CD8 expression was decreased in approximate half of the CD8⁺ T cells after culturing PBMCs isolated from P2 *in vitro* for 24 hours, while the expression on CD8⁺ T cells of unaffected controls remained normal (Fig. 3n). Through gating on CD8^{hi} (CD8⁺ T cells with normal CD8 expression) or CD8^{lo} (CD8⁺ T cells with lower CD8 expression) T cells, we found that in contrast to CD8^{hi} T cells, most of the CD8^{lo} T cells exhibited augmented cleaved caspase-3 (Fig. 3n), indicative of activated apoptosis. In addition, total RIPK1 level in CD8^{lo} T cells decreased which may be

230 caused by caspase-3 cleavage (Fig. 3n). The decreased CD8 expression in patients' T cells and the 231 increases in CD4/CD8 ratio were more prominent after prolonged in vitro culture and after TS or TSZ 232 stimulation compared to that of control (Fig. 3o, Extended Data Fig. 6b-d). The elevation of CD4/CD8 233 ratio induced by TS or TSZ could be inhibited by RIPK1 kinase inhibitor or in situ knockin of WT RIPK1 234 (Fig. 3p-q, Extended Data Fig. 6e-f). In contrast, neither ferroptosis induced by RSL3 nor RIPK1-235 independent apoptosis induced by staurosporine (STS) can differentiate cell death of CD8⁺ T cells from 236 the patients compared to that of unaffected controls (Extended Data Fig. 6g). In addition, the activation 237 of patients' T cells by anti-CD3 antibody stimulation increased CD4/CD8 ratio, which could be reversed 238 by ponatinib or partially reversed by Nec-1s (Fig. 3r-t). Since ponatinib inhibits the kinase activity of 239 RIPK1 and RIPK3²¹, these results suggest that they might play important roles in regulating AICD in 240 the patient T cells bearing K377E/R390G compound RIPK1 mutations. Together, these results suggested 241 that T cells, especially CD8⁺ T cells, were the most susceptible hematopoietic lineage to RIPK1-mediated 242 cell death in patients with the RIPK1 K377E/R390G variants.

243

244 **RIPK1** activation-induced T cell death drives inflammation in myeloid cells

245 Given the differential impact of the RIPK1 K377E/R390G variants on T cells and monocytes, we next 246 investigated cell-cell communication between these two cell types using a transwell system (Fig. 4a). 247 The results showed that patients' T cells induced higher cytokine expression in MDMs comparing to that 248 of T cells isolated from unaffected controls (Fig. 4b, c). However, MDMs from patients showed less 249 response than that of unaffected controls upon culturing with the identical T cells. The impaired 250 inflammatory response by patients' MDMs may be explained by the suppressed NF-kB activation caused 251 by RIPK1 K377E/R390G mutations. Interestingly, patients' T cells could still trigger massive cytokine 252 production in autologous MDMs (Extended Data Fig. 7a). Thus, we conclude that increased cell death 253 by T cells from the patients can act to potentiate the inflammatory response of monocytes and 254 macrophages with RIPK1 K377E/R390G mutations.

255 Previous studies have proposed TNF and IFN γ secreted by chimeric antigen receptor (CAR) T cells 256 as key contributors to the activation of macrophage during cytokine release syndrome (CRS) ²². TNF 257 combined with IFN γ were also reported to be a key inducer of inflammation in patients with severe 258 COVID-19 ²³. Intriguingly, IFN γ and TNF were specifically upregulated in patients' T lymphocytes and 259 NK cells whereas receptors of these two cytokines were highly expressed in myeloid cells (Fig. 4d,

260 Extended Data Fig. 7b, c), providing additional support for T cell-monocyte/macrophage communication 261 through these two receptor-ligand pairs. In comparison to unaffected controls, T cells, especially CD8⁺ 262 T cells from patients, exhibited greater production of IFNy and TNF. The production of these cytokines 263 was further enhanced upon TS or TSZ stimulation (Fig. 4e, Extended Data Fig. 7d). These results 264 indicated that IFNy and TNF produced by activated T cells may be the key factors to initiate the 265 inflammatory response of MDMs. Consistently, increased production of TNF, IL1B and IL6 in MDMs 266 generated from unaffected controls stimulated by either patient T cells or anti-CD3/CD28-activated 267 donor-matched T cells could be partially inhibited by neutralization of IFNy or TNF alone. The cytokine 268 production was completely blocked by combined blockade of IFNy and TNF (Fig. 4f, Extended Data 269 Fig. 7e). Collectively, these data demonstrated that RIPK1 overactivation in CD8⁺ T cells promoted cell 270 death as well as TNF and IFNy secretion to trigger inflammatory cytokine production in MDMs 271 (Extended Data Fig. 7f).

272 In order to validate this model and assess whether the function of RIPK1 K377E and R390G 273 mutations in CD8⁺ T cells was sufficient to induce inflammation, we exploited the Cre-loxp system 274 combined with bone marrow transplantation to conditionally express WT or mutated human RIPK1 in 275 specific hematopoietic compartments (Fig. 4g, Extended Data Fig. 8a). HSCs isolated from donor Cd8a-276 creERT2 mice or Lyz2-creERT2 mice were transduced with lentivirus encoding EF1a-promoted loxp-277 GFP-stop-loxp-TagBFP2-P2A-human RIPK1 expression cassettes (LSL-hRIPK1). Afterwards, 278 transduced HSCs were transplanted into lethally irradiated donor mice followed by tamoxifen induction. 279 Transplantation efficiency and the specificities of Cd8a and Lyz2 promoters were validated (Extended 280 Data Fig. 8b-h). GFP expression in HSCs reflected transduction efficiency, and TagBFP2 confirmed 281 WT/mutated RIPK1 expression in specific cell types upon tamoxifen induction (Extended Data Fig. 9a-282 d). We then evaluated the serum levels of inflammatory cytokines in the recipients. Under basal 283 conditions, serum Tnf and Il-6 levels were higher in mice with $Cd8\alpha^{+}T$ cells expressing mutated RIPK1 284 (K377E, R390G or D324V) than WT RIPK1 and empty vector (EV) controls (Fig. 4h). No significant 285 differences were observed between mice bearing myeloid cells overexpressing EV/WT RIPK1 controls 286 and mutated RIPK1 (Fig. 4i). The result demonstrated the pathogenic function of K377E and R390G as 287 well as the initiator role of T cells in the autoinflammation. We also investigated the function of RIPK1 288 K377E/R390G mutations in myeloid cells. As TLR4 is specially highly expressed in myeloid cells, we 289 assessed the responsiveness of recipients to LPS at a nonlethal dose. The results showed that LPS

challenge led to elevation of Il-6 and Tnf in all groups. Recipients transplanted with HSCs expressing
mutated RIPK1 (K377E, R390G or D324V) under the control of *Lyz2*, but not *Cd8a* promoter displayed
higher serum level of inflammatory cytokines than WT and EV controls under LPS stimulation
(Extended Data Fig. 9e-f), which is consistent with myeloid-specific inactivation of TAK1 that caused
Ripk1 activation and cell death in mouse²⁴. *RIPK1* mutations at D324 ^{3,4}, which could activate RIPK1-dependent cell death, have been reported

- 296 to cause CRIA syndrome, respectively. Therefore, we examined the CD4/CD8 ratio and RIPK1 activation 297 in CRIA patients (CRIA-1 and CRIA-2) to verify our model. Similar to patients with RIPK1 298 K377E/R390G variants, we observed elevated CD4/CD8 ratio paired with increased RIPK1 299 phosphorylation and cleaved caspase-3 in PBMCs from CRIA patients (Fig. 4j-m, Extended Data Fig. 300 10a-b), indicating that CD8⁺ T cell death might be a general phenomenon during the inflammation of 301 CRIA. Notably, in vitro culture also induced decreased CD8 expression in CD8⁺ T cells of CRIA-1 302 (Extended Data Fig. 10c). CD4 and CD8 expression levels in CRIA patients' T cells were validated by 303 CyTOF and CD8 expression decreased more in CD8⁺ TEMRA cells than other subsets, reflecting higher 304 levels of cell death in CD8⁺ TEMRA cells (Extended Data Fig. 10d-g).
- 305

306 Targeted therapies

307 As TNF and IFNy were considered to mediate the inflammatory cytokine production of myeloid cells, 308 we compared the treatment effectiveness of TNF inhibitor adalimumab with tocilizumab which blocks 309 the signaling of IL-6 mainly produced by myeloid cells in patients (Fig. 4n-o). Both P1 and P2 responded 310 to tocilizumab and showed marked alleviation of the elevated temperature and skin rashes and the 311 inflammatory indexes including abnormal CRP, WBC, neutrophil and lymphocyte. However, the serum 312 levels of TNF in both patients could not be suppressed by tocilizumab. TNF-targeting therapy is projected 313 to partially interrupt the communication between T cells and monocytes/macrophages in our model. P2 314 responded to anti-TNF therapy with reduced severity of the symptoms and decreased frequency of fevers. 315 However, adalimumab had limited effects on WBC and lymphocyte counts as well as symptoms of P1 316 as adalimumab alone was not enough to suppress serum levels of IL-6 (Fig. 4o), in accordance with the 317 partial inhibitory effect of adalimumab on IL-6 produced by MDMs in the co-culture assay.

318

319 Discussion

320 This is the first report of biallelic mutations K377E/R390G in RIPK1 leading to early-onset SAIDs with 321 manifestations of periodic fever, intermittent lymphadenopathy, skin rashes and VEO-IBD. Mutation at 322 K377 blocks K63-linked ubiquitination of RIPK1, while function of *RIPK1* R390 has not been reported. 323 Here, we revealed that both K377E and R390G mutations lead to defects in TNF-RSC formation and 324 activation of RIPK1, which promote cell death and inflammation. Since K377E and R390G are the 325 recessive gain-of-function (GOF) mutations of *RIPK1*, as are the previously described caspase cleavage 326 resistance variants, we termed these two conditions as "Gain-of-function RIPK1 variants-induced 327 autoinflammatory syndrome (GRIA)".

328 The condition in our study is inherited in an autosomal recessive (AR) pattern, which is different 329 from autosomal dominantly inherited CRIA syndrome even if they share similar manifestations. 330 Mutation in *RIPK1* D324 does not impair NF-κB pathway³⁻⁵; in contrast, compound heterozygous 331 mutations in *RIPK1* K377/R390 suppressed NF- κ B activation, indicating that the autoinflammation 332 caused by these mutations is not directly induced by dysregulation of NF-kB. The evidence that PBMCs 333 and MEFs carrying heterozygous mutations in D324 as well as T cells carrying compound heterozygous 334 variants in RIPK1 K377/R390 instead of heterozygous variant are hypersensitive to TNF-induced cell 335 death support the inheritance pattern of the two conditions^{3,4}. Thus, excessive RIPK1-mediated cell death 336 triggered by heterozygous D324 mutations or biallelic K377E and R390G mutations is supposed to be 337 the inducer of autoinflammation. Mutations of genes such as TBK18, OTULIN, HOIP, HOIL1 and 338 SHARPIN9, haven been shown to cause several SAIDs. Variants of these genes have been studied in 339 murine models and are revealed to cause embryonic lethality attributed by enhanced cell death^{17,25-27}. In 340 contrast, patients with programmed cell death-driven SAIDs (PCD-driven SAIDs) only manifest periodic 341 inflammation with excessive production of proinflammatory cytokines such as IL-6 and TNF. 342 Overactivation of cell death has been observed in the cells derived from these patients, supporting an 343 important role of cell death in the pathogenesis of SAIDs. However, how programmed cell death induces 344 autoinflammation in human diseases remains uninvestigated.

345Our study provides a mechanism that K377E/R390G variants of *RIPK1* induce CD8+ T cell death346to cause SAIDs. CD8+ T cells bearing K377E/R390G have the propensity to be activated and expanded,347and then enter the contraction phase induced by programmed cell death. During this process, CD8+ T348cells secret massive TNF and IFNγ which prime monocytes or macrophages to produce proinflammatory349cytokines. The accumulation of the inflammatory cytokines such as group 2 cytokines secreted from

350 monocytes would induce the onset of fever. At the same time, inflammation accelerates the proliferation 351 of T lymphocytes and autoinflammation with a positive feedback loop that amplifies the inflammatory 352 reaction (Extended Data Fig. 7f). Eventually, inflammation is terminated with the decrease of activated 353 CD8⁺ T cells. Thus, we hypothesize that dynamics of CD4/CD8 ratio is correlated with the inflammatory 354 state. Consistently, we captured once the resting stage before T cell expansion of P2 as well as CRIA-2 355 with the normal ranges of WBC, lymphocyte counts and CD4/CD8 ratio. Therefore, increased CD4/CD8 356 ratio combined with augmented RIPK1 activation in T cells are supposed to be biomarkers for PCD-357 driven inflammation. This evidence for diagnosis is verified in patients with CRIA syndrome. But it is worth noting that intensive gating strategy is required as CD8^{lo} T cells representing the dying CD8⁺ T 358 359 cells may be considered as CD8⁺ T cells by conventional gating strategy, leading to the falsely normal 360 CD4/CD8 ratio. Since RIPK1 activation-induced AICD of T cells trigger the inflammation in SAID 361 patients carrying RIPK1 GOF variants, RIPK1 kinase inhibitors or RIPK1 proteolysis targeting chimeras 362 degraders may provide a promising strategy for the treatment of SAID induced by RIPK1 363 overactivation¹¹.

364 GRIA syndrome is characterized by selective cell death of CD8⁺ T cells as reflected by the elevation 365 of CD4/CD8 ratio in peripheral lymphocytes. This process is remarkably similar to the contraction phase 366 of CD8⁺ T cells following infections as most effector CD8⁺ T cells undergo programmed cell death after 367 clonal expansion upon antigen-induced activation. Interestingly, intermittent fever with viremia has been 368 shown to be correlated with CD4/CD8 ratio, which is similar to high CD4/CD8 ratio in K377E/R390G 369 patients during flare²⁸. Although the two diseases have completely different mechanism, it is worthwhile 370 to note that almost 14 days were needed for CD8⁺ T cells to undergo expansion and contraction upon 371 antigen stimulation²⁹, which is identical to the period of intermittent fever in GRIA patients.

372 Taken together, our findings provide a new insight that not only innate immune system, but also 373 adaptive immune cells can play a causative role in the onset of SAIDs. We demonstrate that myeloid 374 cells, such as monocytes and macrophages, act as executors of PCD-driven SAIDs for that they take 375 responsibility to produce excessive cytokines to induce autoinflammation. This finding supports the 376 notion that SAIDs is induced by dysregulation of innate immune system. In addition, we also highlight 377 the essential role of T cells in PCD-driven SAIDs as they are the most sensitive hematopoietic 378 compartments to cell death and has the predisposition to undergo AICD which motivate inflammatory 379 response of myeloid cells, indicating the importance of cell-cell communication in pathogenesis of PCD-

driven SAIDs. Hence, blockade of communication between T cells and myeloid cells could be apromising therapeutic strategy for PCD-driven SAIDs.

382

383 Acknowledgements

We thank the patients, their families and the unaffected controls for their support during this research study. We also thank the core facility of the Life Sciences Institute, Zhejiang University, and core facilities of Liangzhu Laboratory, Zhejiang University. The works of Q.Z. were supported by grants 82225022, 32141004 and 32321002 from the National Natural Science Foundation of China. The works of X.Y. were supported by the Hundred-Talent Program of Zhejiang University. J.D. received grant 32300618 from the National Natural Science Foundation of China. J.W. received the grant 2023M733104 from China Postdoctoral Science Foundation. L.G. received the grant LHDMY23H100005 from

- 391 Zhejiang Provincial Natural Science Foundation of China.
- 392

393 Author contributions

- 394 Q.Z., X.Y., and J.Y. directed and supervised the research. J.D., T.J., and G.S. contributed equally. J.D.
- 395 and T.J. designed the study, performed experiments and analyzed most of the data. X.H., J.W., and C.L.
- analyzed data. S.W. and J.Z. performed experiments. G.S., W.Z., Q.Z., J.Y., P.Y.L., D.Z., M.L., Y.X., T.Y.,
- 397 M.W., J.Z., M.K., and J.L. enrolled the patients, collected and interpreted clinical information. J.D., T.J.,
- 398 Q.Z., J.Y., and P.Y.L. wrote the manuscript, with input from others. All authors contributed to the review
- 399 and approval of the manuscript.

400

401 **Competing interests**

402 J.Y. is a consultant of Denali Therapeutics. The rest of authors declare no competing financial interests.

403

404 References

- 4051Manthiram, K., Zhou, Q., Aksentijevich, I. & Kastner, D. L. The monogenic autoinflammatory406diseases define new pathways in human innate immunity and inflammation. Nat Immunol 18,407832-842 (2017). https://doi.org:10.1038/ni.3777
- 4082Zhang, J., Lee, P. Y., Aksentijevich, I. & Zhou, Q. How to Build a Fire: The Genetics of409Autoinflammatory Diseases. Annu Rev Genet (2023). https://doi.org:10.1146/annurev-genet-410030123-084224
- 411 3 Lalaoui, N. et al. Mutations that prevent caspase cleavage of RIPK1 cause autoinflammatory

412		disease. Nature 577, 103-108 (2020). https://doi.org:10.1038/s41586-019-1828-5
413	4	Tao, P. <i>et al.</i> A dominant autoinflammatory disease caused by non-cleavable variants of RIPK1.
414		<i>Nature</i> 577 , 109-114 (2020). https://doi.org:10.1038/s41586-019-1830-y
415	5	Tapiz, I. R. A. J. et al. Characterization of Novel Pathogenic Variants Leading to Caspase-8
416		Cleavage-Resistant RIPK1-Induced Autoinflammatory Syndrome. J Clin Immunol 42, 1421-
417		1432 (2022). https://doi.org:10.1007/s10875-022-01298-2
418	6	Cuchet-Lourenco, D. <i>et al.</i> Biallelic RIPK1 mutations in humans cause severe
419		immunodeficiency, arthritis, and intestinal inflammation. <i>Science</i> 361 , 810-813 (2018).
420		https://doi.org:10.1126/science.aar2641
421	7	Li, Y. et al. Human RIPK1 deficiency causes combined immunodeficiency and inflammatory
422		bowel diseases. Proc Natl Acad Sci U S A 116, 970-975 (2019).
423		https://doi.org:10.1073/pnas.1813582116
424	8	Taft, J. et al. Human TBK1 deficiency leads to autoinflammation driven by TNF-induced cell
425		death. Cell 184, 4447-4463 e4420 (2021). https://doi.org:10.1016/j.cell.2021.07.026
426	9	Oda, H. <i>et al.</i> Human LUBAC deficiency leads to autoinflammation and immunodeficiency by
427		dysregulation in TNF-mediated cell death. <i>medRxiv</i> , 2022.2011.2009.22281431 (2022).
428		https://doi.org:10.1101/2022.11.09.22281431
429	10	Xu, D., Zou, C. & Yuan, J. Genetic Regulation of RIPK1 and Necroptosis. Annu Rev Genet 55,
430		235-263 (2021). https://doi.org:10.1146/annurev-genet-071719-022748
431	11	Mifflin, L., Ofengeim, D. & Yuan, J. Receptor-interacting protein kinase 1 (RIPK1) as a
432		therapeutic target. <i>Nat Rev Drug Discov</i> 19 , 553-571 (2020). https://doi.org:10.1038/s41573-
433		020-0071-v
434	12	Degterev, A., Ofengeim, D. & Yuan, J. Targeting RIPK1 for the treatment of human diseases.
434 435	12	Degterev, A., Ofengeim, D. & Yuan, J. Targeting RIPK1 for the treatment of human diseases. <i>Proc Natl Acad Sci U S A</i> 116 , 9714-9722 (2019). <u>https://doi.org:10.1073/pnas.1901179116</u>
434 435 436	12 13	Degterev, A., Ofengeim, D. & Yuan, J. Targeting RIPK1 for the treatment of human diseases. <i>Proc Natl Acad Sci U S A</i> 116 , 9714-9722 (2019). <u>https://doi.org:10.1073/pnas.1901179116</u> Tang, Y. <i>et al.</i> K63-linked ubiquitination regulates RIPK1 kinase activity to prevent cell death
434 435 436 437	12 13	Degterev, A., Ofengeim, D. & Yuan, J. Targeting RIPK1 for the treatment of human diseases. <i>Proc Natl Acad Sci U S A</i> 116 , 9714-9722 (2019). <u>https://doi.org:10.1073/pnas.1901179116</u> Tang, Y. <i>et al.</i> K63-linked ubiquitination regulates RIPK1 kinase activity to prevent cell death during embryogenesis and inflammation. <i>Nat Commun</i> 10 , 4157 (2019).
434 435 436 437 438	12 13	Degterev, A., Ofengeim, D. & Yuan, J. Targeting RIPK1 for the treatment of human diseases. <i>Proc Natl Acad Sci U S A</i> 116 , 9714-9722 (2019). <u>https://doi.org:10.1073/pnas.1901179116</u> Tang, Y. <i>et al.</i> K63-linked ubiquitination regulates RIPK1 kinase activity to prevent cell death during embryogenesis and inflammation. <i>Nat Commun</i> 10 , 4157 (2019). <u>https://doi.org:10.1038/s41467-019-12033-8</u>
434 435 436 437 438 439	12 13 14	Degterev, A., Ofengeim, D. & Yuan, J. Targeting RIPK1 for the treatment of human diseases. <i>Proc Natl Acad Sci U S A</i> 116 , 9714-9722 (2019). <u>https://doi.org:10.1073/pnas.1901179116</u> Tang, Y. <i>et al.</i> K63-linked ubiquitination regulates RIPK1 kinase activity to prevent cell death during embryogenesis and inflammation. <i>Nat Commun</i> 10 , 4157 (2019). <u>https://doi.org:10.1038/s41467-019-12033-8</u> Zhang, X. <i>et al.</i> Ubiquitination of RIPK1 suppresses programmed cell death by regulating
 434 435 436 437 438 439 440 	12 13 14	Degterev, A., Ofengeim, D. & Yuan, J. Targeting RIPK1 for the treatment of human diseases. <i>Proc Natl Acad Sci U S A</i> 116 , 9714-9722 (2019). <u>https://doi.org:10.1073/pnas.1901179116</u> Tang, Y. <i>et al.</i> K63-linked ubiquitination regulates RIPK1 kinase activity to prevent cell death during embryogenesis and inflammation. <i>Nat Commun</i> 10 , 4157 (2019). <u>https://doi.org:10.1038/s41467-019-12033-8</u> Zhang, X. <i>et al.</i> Ubiquitination of RIPK1 suppresses programmed cell death by regulating RIPK1 kinase activation during embryogenesis. <i>Nat Commun</i> 10 , 4158 (2019).
 434 435 436 437 438 439 440 441 	12 13 14	Degterev, A., Ofengeim, D. & Yuan, J. Targeting RIPK1 for the treatment of human diseases. <i>Proc Natl Acad Sci U S A</i> 116 , 9714-9722 (2019). <u>https://doi.org:10.1073/pnas.1901179116</u> Tang, Y. <i>et al.</i> K63-linked ubiquitination regulates RIPK1 kinase activity to prevent cell death during embryogenesis and inflammation. <i>Nat Commun</i> 10 , 4157 (2019). <u>https://doi.org:10.1038/s41467-019-12033-8</u> Zhang, X. <i>et al.</i> Ubiquitination of RIPK1 suppresses programmed cell death by regulating RIPK1 kinase activation during embryogenesis. <i>Nat Commun</i> 10 , 4158 (2019). <u>https://doi.org:10.1038/s41467-019-11839-w</u>
 434 435 436 437 438 439 440 441 442 	12 13 14 15	 Degterev, A., Ofengeim, D. & Yuan, J. Targeting RIPK1 for the treatment of human diseases. <i>Proc Natl Acad Sci U S A</i> 116, 9714-9722 (2019). <u>https://doi.org:10.1073/pnas.1901179116</u> Tang, Y. <i>et al.</i> K63-linked ubiquitination regulates RIPK1 kinase activity to prevent cell death during embryogenesis and inflammation. <i>Nat Commun</i> 10, 4157 (2019). <u>https://doi.org:10.1038/s41467-019-12033-8</u> Zhang, X. <i>et al.</i> Ubiquitination of RIPK1 suppresses programmed cell death by regulating RIPK1 kinase activation during embryogenesis. <i>Nat Commun</i> 10, 4158 (2019). <u>https://doi.org:10.1038/s41467-019-11839-w</u> Kist, M. <i>et al.</i> Impaired RIPK1 ubiquitination sensitizes mice to TNF toxicity and inflammatory
 434 435 436 437 438 439 440 441 442 443 	12 13 14 15	 Degterev, A., Ofengeim, D. & Yuan, J. Targeting RIPK1 for the treatment of human diseases. <i>Proc Natl Acad Sci U S A</i> 116, 9714-9722 (2019). <u>https://doi.org:10.1073/pnas.1901179116</u> Tang, Y. <i>et al.</i> K63-linked ubiquitination regulates RIPK1 kinase activity to prevent cell death during embryogenesis and inflammation. <i>Nat Commun</i> 10, 4157 (2019). <u>https://doi.org:10.1038/s41467-019-12033-8</u> Zhang, X. <i>et al.</i> Ubiquitination of RIPK1 suppresses programmed cell death by regulating RIPK1 kinase activation during embryogenesis. <i>Nat Commun</i> 10, 4158 (2019). <u>https://doi.org:10.1038/s41467-019-11839-w</u> Kist, M. <i>et al.</i> Impaired RIPK1 ubiquitination sensitizes mice to TNF toxicity and inflammatory cell death. <i>Cell Death Differ</i> 28, 985-1000 (2021). <u>https://doi.org:10.1038/s41418-020-00629-</u>
 434 435 436 437 438 439 440 441 442 443 444 	12 13 14 15	 Degterev, A., Ofengeim, D. & Yuan, J. Targeting RIPK1 for the treatment of human diseases. <i>Proc Natl Acad Sci U S A</i> 116, 9714-9722 (2019). <u>https://doi.org:10.1073/pnas.1901179116</u> Tang, Y. <i>et al.</i> K63-linked ubiquitination regulates RIPK1 kinase activity to prevent cell death during embryogenesis and inflammation. <i>Nat Commun</i> 10, 4157 (2019). <u>https://doi.org:10.1038/s41467-019-12033-8</u> Zhang, X. <i>et al.</i> Ubiquitination of RIPK1 suppresses programmed cell death by regulating RIPK1 kinase activation during embryogenesis. <i>Nat Commun</i> 10, 4158 (2019). <u>https://doi.org:10.1038/s41467-019-11839-w</u> Kist, M. <i>et al.</i> Impaired RIPK1 ubiquitination sensitizes mice to TNF toxicity and inflammatory cell death. <i>Cell Death Differ</i> 28, 985-1000 (2021). <u>https://doi.org:10.1038/s41418-020-00629-3</u>
 434 435 436 437 438 439 440 441 442 443 444 445 	12 13 14 15 16	 Degterev, A., Ofengeim, D. & Yuan, J. Targeting RIPK1 for the treatment of human diseases. <i>Proc Natl Acad Sci U S A</i> 116, 9714-9722 (2019). <u>https://doi.org:10.1073/pnas.1901179116</u> Tang, Y. <i>et al.</i> K63-linked ubiquitination regulates RIPK1 kinase activity to prevent cell death during embryogenesis and inflammation. <i>Nat Commun</i> 10, 4157 (2019). <u>https://doi.org:10.1038/s41467-019-12033-8</u> Zhang, X. <i>et al.</i> Ubiquitination of RIPK1 suppresses programmed cell death by regulating RIPK1 kinase activation during embryogenesis. <i>Nat Commun</i> 10, 4158 (2019). <u>https://doi.org:10.1038/s41467-019-11839-w</u> Kist, M. <i>et al.</i> Impaired RIPK1 ubiquitination sensitizes mice to TNF toxicity and inflammatory cell death. <i>Cell Death Differ</i> 28, 985-1000 (2021). <u>https://doi.org:10.1038/s41418-020-00629-3</u> Ea, C. K., Deng, L., Xia, Z. P., Pineda, G. & Chen, Z. J. Activation of IKK by TNFalpha requires
 434 435 436 437 438 439 440 441 442 443 444 445 446 	12 13 14 15 16	 Degterev, A., Ofengeim, D. & Yuan, J. Targeting RIPK1 for the treatment of human diseases. <i>Proc Natl Acad Sci U S A</i> 116, 9714-9722 (2019). <u>https://doi.org:10.1073/pnas.1901179116</u> Tang, Y. <i>et al.</i> K63-linked ubiquitination regulates RIPK1 kinase activity to prevent cell death during embryogenesis and inflammation. <i>Nat Commun</i> 10, 4157 (2019). <u>https://doi.org:10.1038/s41467-019-12033-8</u> Zhang, X. <i>et al.</i> Ubiquitination of RIPK1 suppresses programmed cell death by regulating RIPK1 kinase activation during embryogenesis. <i>Nat Commun</i> 10, 4158 (2019). <u>https://doi.org:10.1038/s41467-019-11839-w</u> Kist, M. <i>et al.</i> Impaired RIPK1 ubiquitination sensitizes mice to TNF toxicity and inflammatory cell death. <i>Cell Death Differ</i> 28, 985-1000 (2021). <u>https://doi.org:10.1038/s41418-020-00629-3</u> Ea, C. K., Deng, L., Xia, Z. P., Pineda, G. & Chen, Z. J. Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. <i>Mol Cell</i> 22, 245-257
 434 435 436 437 438 439 440 441 442 443 444 445 446 447 	12 13 14 15 16	 Degterev, A., Ofengeim, D. & Yuan, J. Targeting RIPK1 for the treatment of human diseases. <i>Proc Natl Acad Sci U S A</i> 116, 9714-9722 (2019). <u>https://doi.org:10.1073/pnas.1901179116</u> Tang, Y. <i>et al.</i> K63-linked ubiquitination regulates RIPK1 kinase activity to prevent cell death during embryogenesis and inflammation. <i>Nat Commun</i> 10, 4157 (2019). <u>https://doi.org:10.1038/s41467-019-12033-8</u> Zhang, X. <i>et al.</i> Ubiquitination of RIPK1 suppresses programmed cell death by regulating RIPK1 kinase activation during embryogenesis. <i>Nat Commun</i> 10, 4158 (2019). <u>https://doi.org:10.1038/s41467-019-11839-w</u> Kist, M. <i>et al.</i> Impaired RIPK1 ubiquitination sensitizes mice to TNF toxicity and inflammatory cell death. <i>Cell Death Differ</i> 28, 985-1000 (2021). <u>https://doi.org:10.1038/s41418-020-00629-3</u> Ea, C. K., Deng, L., Xia, Z. P., Pineda, G. & Chen, Z. J. Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. <i>Mol Cell</i> 22, 245-257 (2006). <u>https://doi.org:10.1016/j.molcel.2006.03.026</u>
 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 	12 13 14 15 16 17	 Degterev, A., Ofengeim, D. & Yuan, J. Targeting RIPK1 for the treatment of human diseases. <i>Proc Natl Acad Sci U S A</i> 116, 9714-9722 (2019). https://doi.org:10.1073/pnas.1901179116 Tang, Y. et al. K63-linked ubiquitination regulates RIPK1 kinase activity to prevent cell death during embryogenesis and inflammation. <i>Nat Commun</i> 10, 4157 (2019). https://doi.org:10.1038/s41467-019-12033-8 Zhang, X. et al. Ubiquitination of RIPK1 suppresses programmed cell death by regulating RIPK1 kinase activation during embryogenesis. <i>Nat Commun</i> 10, 4158 (2019). https://doi.org:10.1038/s41467-019-11839-w Kist, M. et al. Impaired RIPK1 ubiquitination sensitizes mice to TNF toxicity and inflammatory cell death. <i>Cell Death Differ</i> 28, 985-1000 (2021). https://doi.org:10.1038/s41418-020-00629-3 Ea, C. K., Deng, L., Xia, Z. P., Pineda, G. & Chen, Z. J. Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. <i>Mol Cell</i> 22, 245-257 (2006). https://doi.org:10.1016/j.molcel.2006.03.026 Xu, D. et al. TBK1 Suppresses RIPK1-Driven Apoptosis and Inflammation during
 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 	12 13 14 15 16 17	 Degterev, A., Ofengeim, D. & Yuan, J. Targeting RIPK1 for the treatment of human diseases. <i>Proc Natl Acad Sci U S A</i> 116, 9714-9722 (2019). https://doi.org:10.1073/pnas.1901179116 Tang, Y. <i>et al.</i> K63-linked ubiquitination regulates RIPK1 kinase activity to prevent cell death during embryogenesis and inflammation. <i>Nat Commun</i> 10, 4157 (2019). https://doi.org:10.1038/s41467-019-12033-8 Zhang, X. <i>et al.</i> Ubiquitination of RIPK1 suppresses programmed cell death by regulating RIPK1 kinase activation during embryogenesis. <i>Nat Commun</i> 10, 4158 (2019). https://doi.org:10.1038/s41467-019-11839-w Kist, M. <i>et al.</i> Impaired RIPK1 ubiquitination sensitizes mice to TNF toxicity and inflammatory cell death. <i>Cell Death Differ</i> 28, 985-1000 (2021). https://doi.org:10.1038/s41418-020-00629-3 Ea, C. K., Deng, L., Xia, Z. P., Pineda, G. & Chen, Z. J. Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. <i>Mol Cell</i> 22, 245-257 (2006). https://doi.org:10.1016/j.molcel.2006.03.026 Xu, D. <i>et al.</i> TBK1 Suppresses RIPK1-Driven Apoptosis and Inflammation during Development and in Aging. <i>Cell</i> 174, 1477-1491 e1419 (2018).
 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 	12 13 14 15 16 17	 Degterev, A., Ofengeim, D. & Yuan, J. Targeting RIPK1 for the treatment of human diseases. <i>Proc Natl Acad Sci U S A</i> 116, 9714-9722 (2019). <u>https://doi.org:10.1073/pnas.1901179116</u> Tang, Y. <i>et al.</i> K63-linked ubiquitination regulates RIPK1 kinase activity to prevent cell death during embryogenesis and inflammation. <i>Nat Commun</i> 10, 4157 (2019). <u>https://doi.org:10.1038/s41467-019-12033-8</u> Zhang, X. <i>et al.</i> Ubiquitination of RIPK1 suppresses programmed cell death by regulating RIPK1 kinase activation during embryogenesis. <i>Nat Commun</i> 10, 4158 (2019). <u>https://doi.org:10.1038/s41467-019-11839-w</u> Kist, M. <i>et al.</i> Impaired RIPK1 ubiquitination sensitizes mice to TNF toxicity and inflammatory cell death. <i>Cell Death Differ</i> 28, 985-1000 (2021). <u>https://doi.org:10.1038/s41418-020-00629-3</u> Ea, C. K., Deng, L., Xia, Z. P., Pineda, G. & Chen, Z. J. Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. <i>Mol Cell</i> 22, 245-257 (2006). <u>https://doi.org:10.1016/j.molcel.2006.03.026</u> Xu, D. <i>et al.</i> TBK1 Suppresses RIPK1-Driven Apoptosis and Inflammation during Development and in Aging. <i>Cell</i> 174, 1477-1491 e1419 (2018). <u>https://doi.org:10.1016/j.cell.2018.07.041</u>
 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 	12 13 14 15 16 17 18	 Degterev, A., Ofengeim, D. & Yuan, J. Targeting RIPK1 for the treatment of human diseases. <i>Proc Natl Acad Sci U S A</i> 116, 9714-9722 (2019). https://doi.org:10.1073/pnas.1901179116 Tang, Y. et al. K63-linked ubiquitination regulates RIPK1 kinase activity to prevent cell death during embryogenesis and inflammation. <i>Nat Commun</i> 10, 4157 (2019). https://doi.org:10.1038/s41467-019-12033-8 Zhang, X. et al. Ubiquitination of RIPK1 suppresses programmed cell death by regulating RIPK1 kinase activation during embryogenesis. <i>Nat Commun</i> 10, 4158 (2019). https://doi.org:10.1038/s41467-019-11839-w Kist, M. et al. Impaired RIPK1 ubiquitination sensitizes mice to TNF toxicity and inflammatory cell death. <i>Cell Death Differ</i> 28, 985-1000 (2021). https://doi.org:10.1038/s41418-020-00629-3 Ea, C. K., Deng, L., Xia, Z. P., Pineda, G. & Chen, Z. J. Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. <i>Mol Cell</i> 22, 245-257 (2006). https://doi.org:10.1016/j.molcel.2006.03.026 Xu, D. et al. TBK1 Suppresses RIPK1-Driven Apoptosis and Inflammation during Development and in Aging. <i>Cell</i> 174, 1477-1491 e1419 (2018). https://doi.org:10.1016/j.cell.2018.07.041
 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 	12 13 14 15 16 17 18	 Degterev, A., Ofengeim, D. & Yuan, J. Targeting RIPK1 for the treatment of human diseases. <i>Proc Natl Acad Sci U S A</i> 116, 9714-9722 (2019). <u>https://doi.org:10.1073/pnas.1901179116</u> Tang, Y. <i>et al.</i> K63-linked ubiquitination regulates RIPK1 kinase activity to prevent cell death during embryogenesis and inflammation. <i>Nat Commun</i> 10, 4157 (2019). <u>https://doi.org:10.1038/s41467-019-12033-8</u> Zhang, X. <i>et al.</i> Ubiquitination of RIPK1 suppresses programmed cell death by regulating RIPK1 kinase activation during embryogenesis. <i>Nat Commun</i> 10, 4158 (2019). <u>https://doi.org:10.1038/s41467-019-11839-w</u> Kist, M. <i>et al.</i> Impaired RIPK1 ubiquitination sensitizes mice to TNF toxicity and inflammatory cell death. <i>Cell Death Differ</i> 28, 985-1000 (2021). <u>https://doi.org:10.1038/s41418-020-00629-3</u> Ea, C. K., Deng, L., Xia, Z. P., Pineda, G. & Chen, Z. J. Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. <i>Mol Cell</i> 22, 245-257 (2006). <u>https://doi.org:10.1016/j.molcel.2006.03.026</u> Xu, D. <i>et al.</i> TBK1 Suppresses RIPK1-Driven Apoptosis and Inflammation during Development and in Aging. <i>Cell</i> 174, 1477-1491 e1419 (2018). <u>https://doi.org:10.1016/j.cell.2018.07.041</u> Feltham, R. <i>et al.</i> Mind Bomb Regulates Cell Death during TNF Signaling by Suppressing RIPK1's Cytotoxic Potential. <i>Cell Rep</i> 23, 470-484 (2018).
 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 	12 13 14 15 16 17 18	 Degterev, A., Ofengeim, D. & Yuan, J. Targeting RIPK1 for the treatment of human diseases. <i>Proc Natl Acad Sci U S A</i> 116, 9714-9722 (2019). <u>https://doi.org:10.1073/pnas.1901179116</u> Tang, Y. <i>et al.</i> K63-linked ubiquitination regulates RIPK1 kinase activity to prevent cell death during embryogenesis and inflammation. <i>Nat Commun</i> 10, 4157 (2019). <u>https://doi.org:10.1038/s41467-019-12033-8</u> Zhang, X. <i>et al.</i> Ubiquitination of RIPK1 suppresses programmed cell death by regulating RIPK1 kinase activation during embryogenesis. <i>Nat Commun</i> 10, 4158 (2019). <u>https://doi.org:10.1038/s41467-019-11839-w</u> Kist, M. <i>et al.</i> Impaired RIPK1 ubiquitination sensitizes mice to TNF toxicity and inflammatory cell death. <i>Cell Death Differ</i> 28, 985-1000 (2021). <u>https://doi.org:10.1038/s41418-020-00629-3</u> Ea, C. K., Deng, L., Xia, Z. P., Pineda, G. & Chen, Z. J. Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. <i>Mol Cell</i> 22, 245-257 (2006). <u>https://doi.org:10.1016/j.molcel.2006.03.026</u> Xu, D. <i>et al.</i> TBK1 Suppresses RIPK1-Driven Apoptosis and Inflammation during Development and in Aging. <i>Cell</i> 174, 1477-1491 e1419 (2018). <u>https://doi.org:10.1016/j.cell.2018.07.041</u> Feltham, R. <i>et al.</i> Mind Bomb Regulates Cell Death during TNF Signaling by Suppressing RIPK1's Cytotxic Potential. <i>Cell Rep</i> 23, 470-484 (2018). <u>https://doi.org:10.1016/j.celrep.2018.03.054</u>
 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 	12 13 14 15 16 17 18 19	 Degterev, A., Ofengeim, D. & Yuan, J. Targeting RIPK1 for the treatment of human diseases. <i>Proc Natl Acad Sci U S A</i> 116, 9714-9722 (2019). https://doi.org:10.1073/pnas.1901179116 Tang, Y. et al. K63-linked ubiquitination regulates RIPK1 kinase activity to prevent cell death during embryogenesis and inflammation. <i>Nat Commun</i> 10, 4157 (2019). https://doi.org:10.1038/s41467-019-12033-8 Zhang, X. et al. Ubiquitination of RIPK1 suppresses programmed cell death by regulating RIPK1 kinase activation during embryogenesis. <i>Nat Commun</i> 10, 4158 (2019). https://doi.org:10.1038/s41467-019-11839-w Kist, M. et al. Impaired RIPK1 ubiquitination sensitizes mice to TNF toxicity and inflammatory cell death. <i>Cell Death Differ</i> 28, 985-1000 (2021). https://doi.org:10.1038/s41418-020-00629-3 Ea, C. K., Deng, L., Xia, Z. P., Pineda, G. & Chen, Z. J. Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. <i>Mol Cell</i> 22, 245-257 (2006). https://doi.org:10.1016/j.molcel.2006.03.026 Xu, D. et al. TBK1 Suppresses RIPK1-Driven Apoptosis and Inflammation during Development and in Aging. <i>Cell</i> 174, 1477-1491 e1419 (2018). https://doi.org:10.1016/j.cell.2018.07.041 Feltham, R. et al. Mind Bomb Regulates Cell Death during TNF Signaling by Suppressing RIPK1's Cytotoxic Potential. <i>Cell Rep</i> 23, 470-484 (2018). https://doi.org:10.1016/j.celrep.2018.03.054 Zhu, K. et al. Necroptosis promotes cell-autonomous activation of proinflammatory cytokine

456	20	Badovinac, V. P., Porter, B. B. & Harty, J. T. Programmed contraction of CD8(+) T cells after
457		infection. Nat Immunol 3, 619-626 (2002). https://doi.org:10.1038/ni804
458	21	Martens, S., Hofmans, S., Declercq, W., Augustyns, K. & Vandenabeele, P. Inhibitors Targeting
459		RIPK1/RIPK3: Old and New Drugs. Trends Pharmacol Sci 41, 209-224 (2020).
460		https://doi.org:10.1016/j.tips.2020.01.002
461	22	Morris, E. C., Neelapu, S. S., Giavridis, T. & Sadelain, M. Cytokine release syndrome and
462		associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol 22, 85-96 (2022).
463		https://doi.org:10.1038/s41577-021-00547-6
464	23	Karki, R. et al. Synergism of TNF-alpha and IFN-gamma Triggers Inflammatory Cell Death,
465		Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes. Cell
466		184, 149-168 e117 (2021). https://doi.org:10.1016/j.cell.2020.11.025
467	24	Malireddi, R. K. S. et al. TAK1 restricts spontaneous NLRP3 activation and cell death to control
468		myeloid proliferation. J Exp Med 215, 1023-1034 (2018).
469		https://doi.org:10.1084/jem.20171922
470	25	Kelliher, M. A. et al. The death domain kinase RIP mediates the TNF-induced NF-kappaB
471		signal. Immunity 8, 297-303 (1998). https://doi.org:10.1016/s1074-7613(00)80535-x
472	26	Peltzer, N. et al. LUBAC is essential for embryogenesis by preventing cell death and enabling
473		haematopoiesis. Nature 557, 112-117 (2018). https://doi.org:10.1038/s41586-018-0064-8
474	27	Bonnard, M. et al. Deficiency of T2K leads to apoptotic liver degeneration and impaired NF-
475		kappaB-dependent gene transcription. EMBO J 19, 4976-4985 (2000).
476		https://doi.org:10.1093/emboj/19.18.4976
477	28	Murakami, K., Sentsui, H., Shibahara, T. & Yokoyama, T. Reduction of CD4+ and CD8+ T
478		lymphocytes during febrile periods in horses experimentally infected with equine infectious
479		anemia virus. Vet Immunol Immunopathol 67, 131-140 (1999). https://doi.org:10.1016/s0165-
480		<u>2427(98)00225-6</u>
481	29	Prlic, M. & Bevan, M. J. Exploring regulatory mechanisms of CD8+ T cell contraction. Proc
482		Natl Acad Sci USA 105, 16689-16694 (2008). https://doi.org:10.1073/pnas.0808997105
483		

484 Methods

485 Patients

Patients (P1 and P2; CRIA-1 and CRIA-2) were evaluated under protocols approved by Institutional Review Board and Ethical Committee at the Children's Hospital of Zhejiang University School of Medicine (protocol 2021-IRB-172). P1 and P2 were evaluated at Children's Hospital affiliated to the Capital Institute of Pediatrics. All relevant ethical regulations were followed. All patients provided written informed consent.

491

492 Whole exome sequencing and genotyping with sanger sequencing

493 Whole blood genomic DNA was extracted using Maxwell RSC Whole Blood DNA Kit (Promega, 494 AS1520) and 1 µg DNA was used for whole-exome sequencing. WES and data analysis were performed 495 as previously described⁴. For genotyping of other affected or unaffected family members, 437 bp 496 genomic DNA fragment containing RIPK1 K377/R390 was amplified with forward primer 5'-TTGAGA 497 TACAGATTCATGACGGCG-3' and reverse primer 5'-CTGGTGCACTGCATTACCATGAC-3' for 498 sanger sequencing. For genotyping of CRIA patients, 514 bp genomic DNA fragment containing RIPK1 499 D324 was amplified with forward primer 5'-AAATCAGGAAGTGTGAGTCCTACAACC-3' and 500 reverse primer 5'-TGTTCAGAACACTCTATGACTGGTGAG-3' for sanger sequencing.

501

502 Single-cell RNA sequencing

503 PBMCs of patient 1 and patient 2 were freshly isolated and 10000 single-cell were captured by 10X 504 Genomics Chromium for cDNA library preparation according to the manufacturer's instruction. 505 Sequencing was carried out on Illumina NovaSeq PE150 platform by Novogene Company (Beijing, 506 China). The resulting count matrices followed the standard pipeline with default parameters. Further data 507 analysis was performed as previously described ⁴.

508

509 Cell lines, cell isolation, culture and stimulation

The HEK293T cell line was from the American Type Culture Collection (ATCC). Human PBMC samples
were generated from peripheral blood samples using gradient centrifuging with LSM[™] lymphocyte
separation medium (MP Bio, Cat.50494X). Then primary T lymphocytes and monocytes were isolated

513 from PBMCs by negative selection using Pan T Cell Isolation Kit (Miltenyi Biotec, 130-096-535) and

514 Pan Monocyte Isolation Kit (Miltenyi Biotec, 130-096-537) according to manufacturer's instructions.

- 515 SV40-HDFs were derived from skin biopsies of patient or control donors as described and transformed
- 516 by lentiviral transduction of SV40-large T antigen.
- 517 The HEK293T cells, SV40-HDFs were cultured in Dulbecco's Modified Eagle Medium (DMEM, Gibco)
- 518 supplemented with 10% FBS. Human PBMCs, primary T cells and monocytes were cultured in RPMI
- 519 1640 (Gibco) supplemented with 10% FBS. HT-29 cells were cultured in McCoy's 5A medium (Gibco)
- 520 supplemented with 10% FBS.
- 521 Recombinant human TNF (Peprotech, 300-01A) was used to stimulate HT-29 cells (20 ng ml⁻¹), SV40-
- 522 HDFs (20 ng ml⁻¹) and human primary monocytes (50 ng ml⁻¹) for the indicated times. z-VAD-fmk
- 523 (Selleck, S7023, 25 μM), SM-164 (Selleck, S7089, 250 nM) and Nec-1s (Selleck, S8641, 10 μM) were
- 524 used to treat HT-29 cells, human primary T cells and monocytes. Staurosporine (MCE, HY-15141, 100
- 525 nM) and RSL3 (Selleck, S8155, 1 μM) were used to induce apoptosis or ferroptosis in T cells.
- 526

527 Flow cytometry

528 Cells were washed with FACS buffer (0.5% BSA in PBS) and blocked with human Fc Block (BD 529 Biosciences, 564219) followed by staining with antibodies against surface molecules in dark for 30 min 530 at 4 °C. Then cells were washed twice and stained with Fixable Viability Stain 780 (BD Biosciences, 531 565388) to distinguish live versus dead cell. For intracellular staining, cells were fixed and permeabilized 532 with BD Phosflow[™] Fix Buffer and Perm Buffer (BD Biosciences: 557870, 558052) and then washed 533 twice and stained with antibodies against intracellular antigens for 30 min at 4 °C. For pRIPK1 (Ser166) 534 and cleaved caspase-3 staining, cells were incubated with Alexa Fluor 647 labeled goat anti-rabbit IgG 535 (Thermo, A-21244) for 30 min at 4°C after primary antibody staining. Cells were acquired on CytoFlex 536 (Beckman) and data were analyzed using FlowJo software. The following antibody clones were used for 537 staining in flow cytometry analysis: CD3 (SK7, BD Biosciences), CD4 (RPA-T4, BD Biosciences), CD8 538 (RPA-T8, BD Biosciences), CD14 (M5E2, BD Biosciences), CD16 (3G8, BD Biosciences), CD19 539 (SJ25C1, BD Biosciences), CD56 (NCAM16.2, BD Biosciences), IL-1β (JK1B-1, BioLegend), TNF 540 (MAb11, BD Biosciences), IL-6 (MQ2-13A5, BD Biosciences), IFNy (4S.B3, BD Biosciences), Cleaved 541 Caspase-3 (Asp175) (CST, #9661), pRIPK1(Ser166) (D8I3A, CST), RIPK1 (D94C12, CST). 542

543 RNA isolation and real-time RT-PCR

544 Total RNA from cells was extracted using a RNeasy Mini Kit (Qiagen, 74104) according to the 545 manufacturer's instructions. 1 µg RNA was reverse transcribed into cDNA with ReverTra Ace® qPCR 546 RT Master Mix (TOYOBO, FSQ-301). cDNA was then diluted and used for real-time PCR using 2x 547 Universal SYBR Green Fast qPCR Mix (Abclonal, RK21203) with primers targeting IL1B (F, 5'-TGCTCTGGGATTCTCTTCAGC-3'; R, 5'-AAGTCATCCTCATTGCCACTGT-3'), IL6 (F, 5'-548 549 CATCCTCGACGGCATCTCAG-3'; R, 5'-ACCAGGCAAGTCTCCTCATTG-3'), IL8 (F 5'-550 CCAAACCTTTCCACCCCAAA-3'; R, 5'-GAATTCTCAGCCCTCTTCAAAAAC-3') TNF (F, 5'-551 CTCTTCTGCCTGCACTTTG-3'; R, 5'-ATGGGCTACAGGCTTGTCACTC-3'), and GAPDH (F, 552 5'-TCGACAGTCAGCCGCATCTTC-3'; R, 5'-GCGCCCAATACGACCAAATCC-3'). Relative 553 transcription levels were calculated by normalization to GAPDH mRNA.

554

555 Cell viability assay and cell death assay

556 Primary T cells (15000 cells/well), SV40-HDFs (2000 cells/well) or HT-29 (5000 cells/well) were plated 557 in 384-well plate and were stimulated with indicated conditions. General cell viability was measured by 558 using CellTiter-Glo® Luminescent Cell Viability Assay (Promega, G7572) according to the 559 manufacturer's instructions. The percentage of viability was normalized to untreated controls. Cell death 560 detection was performed by direct staining with 0.5 µg/ml Propidium Iodide (PI) and 0.5 µg/ml DAPI 561 for 10 min and imaging with fluorescence microscope. PI positive dead cell was counted and normalized 562 to DAPI counts. For continuous cell death measurement, cells were simulated with indicated conditions 563 and stained with 200 nM Hoechst 33342 (Beyotime, C1022) and 200 nM SYTOX™ Orange (Thermo, 564 S34861) at the same time. The percentage of dead cell was assayed every 1 hour by imaging with BioTek 565 Cytation 3 for 18 hours with 5% CO₂ and 37 °C condition. Results were exported as counts per well to 566 be processed and graphed using Prism 9.

567

568 **Protein array**

569 Semiquantitative analysis of 174 cytokine levels of P2's serum samples before (normal stage) or after 570 (onset, non-flare) the first onset of fever was performed with human Cytokine Array G2000 (RayBiotech) 571 by Novogene Company (Beijing, China). Generally, the cytokine array glass slides were firstly blocked 572 for 1 hour at room temperature and then incubated with 100 μl serum samples at 4 °C overnight. On the 573 second day, the slides were washed with wash buffer and incubated with Biotin-Conjugated Anti-

- 574 Cytokines and HiLyte Plus[™] 555 Streptavidin-Fluor according to the manufacturer's instructions. The
- 575 results were scanned with InnoScan 300 Microarray Scanner (Innopsys) at 532 nm with 10 µm resolution.
- 576 The mean fluorescence intensity (MFI) was calculated and exported for further analysis.
- 577
- 578 Human and mouse cytokines measurement
- 579 Human or mouse serum cytokines were measured by enzyme-linked immunosorbent assay (ELISA)
- 580 (Multi Sciences: 70-EK1280, 70-EK194, 70-EK182HS, 70-EK106HS, 70-EK191, 70-EK180HS, 70-
- 581 EK1F01, 70-EK1F02, EK206HS, EK282HS/2) according to the manufacturer's instructions. T cell
- 582 culture supernatant cytokines were determined by Cytometric Bead Arrays (BD Biosciences) according
- 583 to the manufacturer's instructions. Human serum adenosine deaminase (ADA) activity was measured
- 584 with Boyle colorimetric method by using ADA Activity Assay Kit (Yuanye Bio, R22207) according to
- 585 the manufacturer's instructions. Student's t-test was performed for the statistical analysis.
- 586

587 *In vitro* cell proliferation assay

- Fresh isolated CD3⁺ T cells were labeled with CFSE (Thermo, 65-0850-84, 5 μM) and then stimulated
 with anti-CD3/CD28 beads (T&L Biotechnology) at 1:1 ratio supplemented with hrIL-7 (PrimeGene)
 and hrIL-15 (PrimeGene) in 48-well plates for 96 hours. Then all cells were co-stained with CD4-BB515
- and CD8-BV510 antibodies and analyzed using CytoFlex (Beckman).

592

593 Gene editing of patient T cells

594 Primary T cells isolated from patients were stimulated with anti-CD3/CD28 beads for 3 days. For 595 electroporation, 180 pmol sgRNA and 25 µg Cas9 protein were mixed and incubated for 15 min at room 596 temperature for ribonucleoprotein complexes (RNP) formation. Then 3e6 T cells resuspended in opti-597 MEM were mixed with RNP and 6 µg dsDNA template and electroporated using Gemini X2 (BTX) 598 under the #905 program for human primary T cells. After electroporation, 1 ml warm X-VIVOTM 15 599 Serum-free Hematopoietic Cell Medium (Lonza) supplemented with 10% FBS was immediately added 600 to the cuvette and the mixture was then carefully transferred to 24-well plates for further culture and 601 analysis.

602

603 T cell-MDM co-culture assay

Freshly isolated monocytes were seeded in 24-well plate and differentiated into monocyte-derived macrophages (MDMs) with 20 ng/ml GM-CSF treatment for 10 days. Then, 0.4 μm pore polycarbonate membrane inserts containing T cells isolated from PBMCs of patient or healthy donors were placed into the 24-well plate for the T cell-MDM co-culture at the ratio of 5:1 for 8 hours. Finally, T cells were removed and bottom MDMs were collected for mRNA extraction.

609

610 Mice

611 All mouse studies complied with relevant ethical regulations and approved by Institutional Animal Care

and Use Committee (IACUC) of the Zhejiang University (Registration No.:27043). The Cd8a-creERT2

613 and Lyz2-creERT2 strains on C57BL/6J background were purchased from GemPharmatech. The Rosa26-

614 mTmG strain on C57BL/6J background was purchased from Cyagen. All mice were maintained under

615 specific pathogen-free condition with free access to food and water at Laboratory Animal Center of

616 Zhejiang University.

617

618 HSC isolation, transduction, transplantation, induction and LPS challenge

619 Mouse hematopoietic stem cells (HSC) were isolated from 6- to 8-week-old donor mice using Lineage 620 cell depletion kit (Miltenyi Biotec, 130-090-858) according to manufacturer's instruction. HSCs were 621 plated in 12-well plate and were transduced with lentivirus carrying human RIPK1 inducible expression 622 system (MOI=50). Transduction efficiencies were measured with flow cytometry after 24 hours culturing 623 and 200,000 of transduced HSCs were transplanted into lethally irradiated (4 Gy, 2 times) recipient mice 624 (female, 8 to 12 weeks old). Transplantation efficiencies were validated by flow cytometry analysis after 625 2 weeks. Successfully transplanted mice were injected i.p with 20 mg/ml tamoxifen (MCE, HY-13757A) 626 dissolved in corn oil (MCE, HY-Y1888) every two days for 5 times to induce the expression of WT, 627 K377E, R390G or D324V mutated RIPK1. Then, these mice were injected i.p with 0.5 mg/kg 628 lipopolysaccharide (LPS) (Sigma, L6529) and serum were collected before injection or injected for 2 629 hours. Serum II6 and Tnf were measured by ELISA as described.

630

631 Immunoprecipitation and western blot

632 For TNFR signaling complex (TNF-RSC) enrichment, 5e6 cells were seeded and treated with flag tagged

633 TNF (ENZO, ALX-522-008) for indicated times. The samples were immediately washed with cold PBS

634 and lysed in cold lysis buffer (25 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.5% NP-40, 10% glycerol) with 635 freshly added inhibitors blocking protease and phosphatase (Merck: 4906837001, 4693159001) for 30 636 min. Then samples were cleared through centrifugation at 20000 RCF for 10 min and protein concentrations were determined by Pierce[™] BCA Protein Assay Kits (Thermo, 23225). Then the TNF-637 638 RSC was immunoprecipitated with FLAG M2 magnetic beads (Sigma, M8823) at 4 °C for 4 hours and 639 the protein complex was directly eluted by boiling in 1×SDS loading buffer. For TNF downstream 640 signaling analysis, 4e5 cells were seeded and treated as indicated and then cells were harvested and lysed 641 directly with sample loading buffer. These samples were separated through routine SDS-PAGE and 642 transferred to 0.45 um nitrocellulose membrane (Cytiva, 10600002) and blotted with indicated antibodies.

643

644 **CyTOF**

645 PBMCs were freshly isolated from whole bloods of four patients (P1 and P2; CRIA-1 and CRIA-2) and 646 four unaffected controls, then blocked and labeled with conjugated antibodies as described³¹. Fixed cell 647 samples were resuspend analyzed on a mass cytometer (Helios, Fluidigm). The CyTOF data exported 648 as FCS files were gated in FlowJo (v10.0.7) to remove doublets and CD45⁺ single cells identified by DNA (¹⁹¹Ir and ¹⁹³Ir), ¹⁹⁴Pt and event length. For downstream analysis, 10,000 cells were randomly 649 650 selected from each sample. The raw values of FCS files were transformed using the arcsinh function 651 with a cofactor of 5. Phenograph clustering in cytofkit R package was performed on all subsampled 652 sample events and the transformed values of all events were subjected to t-SNE dimension reduction 653 using R-tsne package^{32,33}.

654

655 Antibodies

The following antibodies were purchased from Cell Signaling Technology: pRIPK1 (S166) (65746),
RIPK1 (3493), pMLKL (S358) (91689), MLKL (14993), pIKKα/β (S176/180) (2697), IKKβ (2370),
Sharpin (12541), pp65 (S65) (3033), p65 (8242), pIκBα (S32) (2859), IκBα (4814), pERK1/2
(T202/Y204) (4370), ERK1/2 (4695), pJNK (T183/Y185) (9251), JNK (9252), HA (3724), cleaved
caspase-3 (D175) (9661), caspase-3 (9662). NEMO (sc-8330) was purchased from Santa Cruz
Biotechnology. GAPDH (SA30-01) was purchased from HUABIO.

662

663 Data availability

664 The raw data of sequencing will be available prior to publication. The other source data that support the

665 findings of this study are available from the corresponding author upon reasonable request.

666 667 30 Carmona-Rivera, C. & Kaplan, M. J. Induction and Quantification of NETosis. Curr Protoc Immunol 115, 14 41 11-14 41 14 (2016). https://doi.org:10.1002/cpim.16 668 669 Wang, Y. et al. Identification of an IL-1 receptor mutation driving autoinflammation directs IL-31 670 1-targeted drug design. Immunity 56, 1485-1501 e1487 (2023). 671 https://doi.org:10.1016/j.immuni.2023.05.014 672 Levine, J. H. et al. Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells 32 673 Prognosis. 184-197 that Correlate with Cell 162, (2015). 674 https://doi.org:10.1016/j.cell.2015.05.047 675 33 Chen, H. et al. Cytofkit: A Bioconductor Package for an Integrated Mass Cytometry Data 676 Analysis Pipeline. PLoS Comput Biol 12. e1005112 (2016). 677 https://doi.org:10.1371/journal.pcbi.1005112



678

Fig. 1 | Compound heterozygous gain-of-function mutations in *RIPK1* causes systemic autoinflammatory
diseases.

681 a, Pedigrees of a family with two patients carrying mutations at RIPK1 K377 and R390. Patient 1 (P1) 682 and patient 2 (P2) were represented with filled symbols. b, Timeline of recurrent fever episodes in P2 683 over 5 weeks. Red dots represented increased temperatures during fever episodes and grey boxes 684 represent the normal temperatures between flares. c, Representative sonographic image showing 685 lymphadenopathy of P2. The diameters of right cervical lymph nodes were marked with dotted yellow 686 line. d, Representative macroscopic image of dermatological manifestations in P1 during acute phase 687 reaction, showing skin rashes (arrows). e, Whole blood cell counts (WBC), C-reactive protein (CRP) and 688 serum amyloid A protein (SAA) were measured serially after the first evaluation of P1 and prednisone 689 treatment (cyan shading) started at the age between 0-5. Horizontal dotted lines indicate age-specific

690 high values for CRP, SAA or high and low values for WBC count. Red dots donate the abnormal values. 691 f, C-reactive protein (CRP), serum ADA enzymatic activity and IL-6, TNF levels of unaffected controls 692 (C, n=13), P1 during prednisone treatment (4 samples taken during flare and 5 samples taken during non-693 flare), P2 (4 samples taken during flare and 6 samples taken during non-flare), unaffected parents 694 carrying heterozygous K377E mutation (K377E/WT, 1 sample from I-2 and 2 samples from II-2) or 695 R390G mutation (R390G/WT, 3 samples from II-3). g, Sanger sequencing chromatograms of RIPK1 696 showed heterozygous base substitutions at p. K377E and p. R390G in whole blood genomic DNA from 697 P1 and P2. h, WebLogo demonstrating conservation of human RIPK1 K377 and R390 across 42 698 vertebrate species. i-l, Cell death of SV40-immortalized human dermal fibroblasts (SV40-HDFs) isolated 699 from three unaffected controls (C1-C3) and P2 were monitored by continuous imaging of SYTOX[™] 700 Orange staining. The SV40-HDFs were treated with T, S, Z as indicated (i). SV40-HDFs was treated 701 with TZ with or without Nec-1s (10 μ M) for 12 hours and immunoblotted with indicated antibodies (j). 702 The TNFR signaling complex (TNF-RSC) were immunoprecipitated with Flag-TNF for 5 or 15 min and 703 immunoblotted with indicated antibodies (k). NF-KB and MAPK activation of SV40-HDFs treated with 704 TNF for 5, 15 or 30 min immunoblotted with indicated antibodies (1). m-p. RIPK1^{-/-} HT-29 cells were 705 lentivirally complemented with HA-RIPK1 wild-type (WT), K377E, R390G and treated with T, S, Z as 706 indicated. Cell viability was measured by CellTiter-Glo luminescent cell viability assay (m). The 707 necroptosis markers (n), TNF-RSC (o) and the NF- κ B and MAPK activation (p) were analyzed in the 708 same way. T denotes 20 ng ml⁻¹ TNF; S denotes 250 nM SM-164; Z denotes 25 µM z-VAD-fmk. Graphs 709 show mean \pm SD. Statistical significance was determined by one-way ANOVA (**m**), **P < 0.01, ***P < 710 0.001.





Fig. 2 | Strong activation of inflammatory signaling in myeloid cells carrying *RIPK1* mutations.

a, Integrated uniform manifold approximation and projection (UMAP) visualization of peripheral blood
mononuclear cells (PBMCs) from three unaffected controls (C1, n=13925 cells; C2, n=11117 cells; C3,
n=12573 cells) and two patients (P1, n=10918 cells; P2, n=8516 cells), marker-based annotation of 15
cell subtypes were colored by cluster identity. LDG, low-density granulocyte; pDC, plasmacytoid

718 dendritic cell; Mo-DC, monocyte-derived dendritic cell; NK, natural killer cell; NKT, natural killer T 719 cell; Eryth, erythrocyte; MK, megakaryocyte. b, Visualization of expressions of IL1B and CXCL8 720 (colored single cells) projecting PBMCs from unaffected controls (C1-C3) and two patients (P1 and P2) 721 on UMAP plots. c, Boxplots of the NF-KB expression score (top panel) and IFN response score (bottom 722 panel) of cell subtypes. d, Heatmap of representative genes downstream of NF-KB and type I IFN 723 pathways in monocyte compartments. Gene names were listed in Extended Data Fig.4d. e, Dot plot 724 showing the biological processes identified with un-regulated gene terms (FDR <0.05) in patients' 725 monocytes compared to that of unaffected controls using DAVID. The size of the circle indicates the 726 gene count enriched in the pathway and the color represents pathway enrichment significance. f, 727 Intracellular cytokine analysis of IL-1 β , IL-6 and IFN γ in monocytes isolated from three unaffected (C1-728 C3) controls and P1. g, qRT-PCR analysis of IL1B, IL6, CXCL8 and TNF mRNA levels in primary 729 monocytes isolated from unaffected controls (n=8-10) and two patients (n=4 from P1 and P2) with or 730 without 10 ng ml⁻¹ TNF for 6 hours. h, CellTiter-Glo luminescent cell viability detection of primary 731 monocytes isolated from unaffected controls (n=12) and two patients (n=3 from P1 and P2) stimulated 732 with T, S, Z for indicated times. i, Statistics of dead M1 macrophages stimulated with TS or TSZ for 24 733 hours by imaging of propidium iodide (PI). M1 macrophages were differentiated from primary 734 monocytes of unaffected controls (n=6) and two patients (n=4 from P1 and P2). Representative images 735 were presented in Extended Data Fig.3e. j, Volcano plot displaying the differentially expressed genes in 736 monocyte compartments between three unaffected controls (C1-C3) and two patients (P1 and P2). 737 Representative suppressive genes of cell death were labeled with red dots and gene names. k, Clusters in 738 the monocyte compartments showing the expression levels of TNFAIP3 and BCL2A1 in three unaffected 739 controls (C1-C3) and two patients (P1 and P2). I, Schematic diagram showing serum cytokine microarray 740 analysis of continuous P2's serum samples before (PS1 and PS2) or after (PS3, flare; PS4 and PS5, non-741 flare) the onset of recurrent fever. m, PCA analysis of sample variance determined by semi-quantitative 742 174 cytokines antibody array on serum samples of C1-C3 from three unaffected controls and PS1-PS5 743 from P2. n, The integrated relative MFI plots of P2's serum cytokine levels. 28 cytokines peaked in PS3 744 were enrich in group 1, 24 cytokines higher than control were enriched in group 2. o, Boxplots exhibiting 745 mRNA expression scores of cytokines of group 1 (left panel) and group 2 (right panel) in indicated cell 746 compartments. Group 1 and group 2 cytokine panels were clustered with the serum cytokine microarray 747 analysis in Extended Data Fig.4. T denotes 10 ng ml⁻¹ TNF; S denotes 250 nM SM164; Z denotes 25 µM

- 748 z-VAD-fmk. All histogram graphs show mean±SD. Statistical significance was determined by two-tailed
- unpaired t-test (**c**, **g**, **i**, **l**) or one-way ANOVA (**h**), ns, P > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001.



751

Fig. 3 | Increased cell death and CD4/CD8 ratio in T cells caused by RIPK1 activation.

a, Average expression values (arcsinh transformed) of cl. Casp-3 across identified peripheral immune cell lineages in PBMCs freshly isolated from four unaffected controls (C) and two patients (P, 1 sample from P1 and 2 samples from P2) by mass cytometry by time-of-flight (CyTOF) analysis. **b-e**,

756 Representative contour plots of cl. Casp-3 (b-c) and histograms of total RIPK1, pRIPK1(S166) (d-e) 757 levels in CD4⁺ T and CD8⁺ T cells in freshly isolated PBMCs from unaffected controls (n=10-12) and 758 patients (n=4 for P1 and P2) (left panel). Summary histograms of cl. Casp-3 and pRIPK1(S166) (right 759 panel) were shown. f, Immunoblotting analysis of primary CD3⁺ T cells isolated from two unaffected 760 controls (C1 and C2) and P1 treated with T and S with or without Z, N for 6 hours. Antibodies as indicated 761 were immunoblotted to show the activation of apoptosis or necroptosis. g, CellTiter-Glo luminescent cell 762 viability detection of primary CD3⁺ T cells isolated from three unaffected controls (C1-C3), two patients 763 (P1 and P2) and their parents treated with TS or TSZ for indicated times, n=4. h, Representative 764 histogram and statistical analysis of surface CD69 expression on CD3⁺ T cells from unaffected controls 765 (n=7) and two patients (n=3 for P1 and P2). i, Serum IFNy, sCD25, sCD95 and CD95L of unaffected 766 controls (C, n=10), two patients (P1, n=5-7; P2, n=4-8) and their parents (n=6-7) as well as two CRIA 767 syndrome patients (n=6) determined by ELISA. j, CD4/CD8 ratio in T cells, percentages and absolute 768 counts of CD3⁺ T, CD4⁺ T, CD8⁺ T cells in whole blood sample of P1 (red dots) and P2 (blue dots) 769 measured using immunophenotyping. k, In vitro expansion of primary T cells isolated from unaffected 770 controls (n=7) and patients (n=3 for P1 and P2) as indicated. Cell numbers were counted every two days 771 post anti-CD3/CD28 dynabeads stimulation. I, Proliferation of CD4⁺ T and CD8⁺ T cells isolated from 772 three unaffected controls (C1-C3) and P1 were analyzed using CFSE staining upon stimulation with anti-773 CD3/CD28 dynabeads for 96 hours. m, Representative histograms of surface CD95 expression on CD3⁺ 774 T cells analyzed with flow cytometry after culturing in vitro for 24 hours. n, Representative contour plots 775 depicting the percentages of CD4⁺ T, CD8⁺ T, double negative T (DNT) and double positive T (DPT) in 776 CD3⁺T cells gated from PBMCs of P2 culturing in vitro for 24 hours. Histograms displaying cl. Casp-3 777 and RIPK1 expression levels in CD8^{hi} T and CD8^{lo} T cells. 0, Representative contour plots and summary histograms showing percentages of CD4⁺ T, CD8⁺ T and CD8^{hi} T cells and CD4/CD8 ratio in CD3⁺ T 778 779 cells isolated from P2 cultured for indicated times. p-q, Representative contour plots showing 780 percentages of CD4⁺ T, CD8⁺ T in CD3⁺ T cells of P2 with (TurboGFP⁺) or without (TurboGFP⁻) 781 restoration using CRISPR/Cas9-mediated in situ knock-in of WT RIPK1-P2A-TurboGFP under 782 stimulation of T with or without S, Z for 6 hours (p). CD4/CD8 ratio in CD3⁺ T cells of unaffected 783 controls (n=7) and two patients (n=3 for P1 and P2) were quantified (q). r-s, Representative contour plots 784 (r) and statistical analysis (s) showing percentages of CD4⁺ T, CD8⁺ T, DNT and DPT cell in CD3⁺ T 785 cells isolated from unaffected control (n=7) and two patients (n=9 for P1 and P2) under the stimulation

- 786 of anti-CD3 antibody (5 μg ml⁻¹) for 72 hours. **t**, Statistical analysis of fold change of CD4 /CD8 ratio in
- 787 CD3⁺ T cells isolated from two patients (n=4 for P1 and P2) under stimulation of anti-CD3 antibody (5
- μg ml⁻¹) with or without 250 nM Ponatinib or 10 μM Nec-1s for 24 hours. For representative contour
- plots, see Extended Data Fig. 6h. T denotes 10 ng ml⁻¹ TNF; S denotes 250 nM SM164; Z denotes 25
- 790 μM z-VAD-fmk; N denotes 10 μM Nec-1s. All histogram graphs show mean±SD. Statistical significance
- 791 was determined by one-way ANOVA (g) or two-tailed unpaired t-test in the rest, *P < 0.05, **P < 0.01,
- 792 ***P < 0.001, ****P < 0.0001.
- 793



794

Fig. 4 | RIPK1 activation causes inflammation through T-Mono axis.

796 a, Schematic diagram of T cell-MDM co-culture system. b-c, qRT-PCR analysis of TNF, IL1B and IL6 797 mRNA levels in GM-CSF-activated monocytes derived macrophages (MDMs) co-cultured with or 798 without T cells for 6 hours. GM-CSF-activated MDMs generated from unaffected control 1 (C1) (left 799 panel) or unaffected control 3 (C3) (right panel) (b) or P1 (c) were co-cultured with donor-matched T 800 cells as well as T cells from other unaffected controls (C2 and C4) or patients as indicated. d, Dot plot of 801 IFNG, TNF in cell subtypes found in scRNA-seq of PBMCs from three unaffected controls and two 802 patients. The size of the circle indicates the percentage of cells positive for gene expression and the color 803 represents the average expression level. e, Representative histograms and statistical analysis of TNF and 804 IFN γ expression in CD8⁺ T cells in PBMCs isolated from unaffected controls (n=6) and patients (n=3 805 for P1 and P2) treated with 10 ng ml⁻¹ TNF (T) with or without 250 nM SM-164 (S), 25 µM z-VAD-fmk 806 (Z) for 24 hours. f, T cells isolated from P2 were co-cultured with MDMs generated from unaffected

807 control in the presence of 10 µg ml⁻¹ adalimumab, 10 µg ml⁻¹ emapalumab alone or in combination for 6 808 hours. TNF, IL1B and IL6 mRNA levels of MDMs were analyzed by qRT-PCR. g, Experimental timeline 809 for generation of HSCs-transplanted mice with conditional overexpression of human WT or mutated 810 RIPK1 K377E, R390G or D324V in CD8 α^+ T cell- or myeloid cell-specific lineage. h-i, ELISA 811 measurement of serum Tnf and Il6 levels in mice specifically overexpressing WT or mutated hRIPK1 in 812 $CD8\alpha^+$ T cells (h) or myeloid cells (i). j-m, Pedigrees of two families with CRIA patients (CRIA-1 and 813 CRIA-2) (j). Patients were represented with filled symbols. Summary histograms of CD4/CD8 ratio in 814 $CD3^+$ T cells of unaffected controls (n=12), CRIA-1 (n=7) and CRIA-2 (n=5) were shown (k). 815 Representative contour plots of cl. Casp-3 (1) and histograms of pRIPK1(S166) (m) protein levels in 816 CD8⁺ T cells in freshly isolated PBMCs from CRIA patients. n-o, Whole blood cell counts (WBC), cell 817 counts and proportions of neutrophil (NE#-NE%) and lymphocyte (LYMPH# -LYMPH%) (n), Serum 818 C-reactive protein (CRP), TNF and IL-6 (0) of P1 (red dots) and P2 (blue dots) measured before and 819 after tocilizumab or adalimumab treatments. The grey area represents the range of unaffected controls. 820 Dots represent each sample and graphs show mean±SD. Statistical significance was determined by two-821 tailed unpaired t-test, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. 822



823

824 Extended Data Fig. 1 | Clinical and genetic information of autoinflammatory patients carrying
825 compound heterozygous GOF mutations in *RIPK1*.

a-c, Cell counts and proportions of neutrophil (NE#-NE%) and lymphocyte (LYMPH# -LYMPH%) (**a**),

827 erythrocyte sedimentation rate (ESR), D-dimer, serum lactate dehydrogenases (LDH) (b), serum C3

828 complement, C4 complement, IgA, IgG, IgM (c) measured serially after the first evaluation of P1 and

829 prednisone treatment (cyan shading) started at the age between 0-5. Horizontal dotted lines indicating

830 age-specific high values for ESR, D-dimer or high and low values for the rest tests. Red dots donate the

831 abnormal values. d, Whole exome sequencing reads covering *RIPK1* p. Lys377Glu (NM_003804.4:

- 832 c.1129A>G) and p. Arg390Gly (NM_003804.4: c.1168C>G) variants in two patients and their parents
- 833 displayed using integrative genomics viewer. e, Sanger sequencing chromatograms of *RIPK1* in whole
- 834 genomic DNA from parents. **f**, Correlating Combined Annotation Dependent Depletion (CADD) scores
- 835 with minor allele frequencies (MAF) for RIPK1 K377E, R390G and D324 variants. Mutation
- 836 significance cutoff (MSC) was show.





838

a, SV40-HDFs isolated from three unaffected controls (C1-C3) and P2 were treated with T with or without S, Z and N as indicated. Cell death were monitored by imaging of SYTOXTM Orange staining. **b-d**, CellTiter-Glo luminescent cell viability detection of $RIPK1^{-/-}$ HT-29 cells complemented with WT or mutated RIPK1 K377R, K377E, R390G, K377E/R390G under stimulation of TZ, TS, TSZ with or without N as indicated (**b-c**). Expression levels of WT or mutated RIPK1 were determined with 100 mutated with TNF for 6

- 846 hours were determined with qRT-PCR. **f-g**, HEK293T cells were transfected with plasmids encoding full
- 847 length/intermediate domain of RIPK1 together with MIB2 or Ub as indicated. ID domain of RIPK1 or
- 848 MIB2 were immunoprecipitated with anti-Flag dynabeads and immunoblotted with indicated antibodies.
- 849 T denotes 20 ng ml⁻¹ TNF; S denotes 250 nM SM-164; Z denotes 25 μM z-VAD-fmk; N denotes 10 μM
- 850 Nec-1s. Graphs show mean±SD.







a, Uniform manifold approximation and projection (UMAP) visualization of peripheral blood mononuclear cells (PBMCs) from three unaffected controls (C1, n=13925 cells; C2, n=11117 cells; C3, n=12573 cells) and two patients (P1, n=10918 cells; P2, n=8516 cells). **b**, Dot plot showing the expression of representative genes downstream of NF- κ B and type I IFN pathways in cell subtypes of PBMCs. The size of the circle indicates the percentage of cells positive for target gene expression and the color represents the average expression levels of genes in clusters. **c**, List of gene names in keeping with Fig.2d. **d**, Gene set enrichment analysis (GSEA) plot of negative regulation of cell death

- 861 (NES=1.328, P<0.01), NF-κB signaling pathway (NES=2.135, P<0.01) and Type I IFN signaling
- 862 pathway (NES=2.023, P<0.01). NES, normalized enrichment score. e, Representative images of dead
- 863 M1 macrophages in keeping with Fig.2i. f, Dot plot of negative regulators of cell death BCL2A1, BCL3,
- 864 BCL6, RNF144B in cell subtypes found in scRNA-seq of PBMCs from three unaffected controls and two
- 865 patients. The size of the circle indicates the percentage of cells positive for gene expression and the color
- 866 represents the average expression levels.
- 867



868

869 Extended Data Fig. 4 | Cytokine array analysis of patient's serum.

870 Images of representative cytokines in group 1 (a), group 2 (c) and group 3 (e-f) clustered from cytokine

- 871 array data according to Fig. 21-n were presented. Typical cytokines were re-validated with ELISA (**b**, **d**)
- and integrated relative MFI plots of group 3 cytokines were shown.



874

875 **Extended Data Fig. 5** | CyTOF profiling of patients' PBMCs.

876 a-b, Integrated t-distributed stochastic neighbor embedding (tSNE) visualization of CyTOF 877 immunophenotyping of PBMCs from four unaffected controls and two patients (a). Major 16 cell 878 lineages from all samples were identified through unsupervised clustering with FlowSOM. tSNE plots 879 showing 10000 cells of representative C1, C2, P1 and P2 with color-indicated cell types (b). c-f, 880 Representative contour plots of cl. Casp-3 (c-d) and histograms of pRIPK1(S166) (e-f) protein levels in 881 CD19⁺ B cells and CD14⁺ monocytes in freshly isolated PBMCs from unaffected controls (n=10) and 882 patients (n=3 for P1 and P2) (left panel). Summary histograms were shown with mean±SD (right panel). 883 g-h, t-distributed stochastic neighbor embedding (tSNE) plot showing the CD69 and CD38 expression 884 in CyTOF analysis. Statistical significance was determined by two-tailed unpaired t-test. ns, P > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001.885 886



888 Extended Data Fig.6 | RIPK1-mediated cell death leads to CD8 decrease in T cells.

887

889 **a**, Percentages and absolute counts of total lymphocytes, $\gamma\delta$ T cells, NKT cells and B cells from whole 890 blood of P1 (red dots) and P2 (blue dots) measured by immunophenotyping. b, Representative contour 891 plots showing percentages of CD8^{hi} T, CD8^{lo} T, CD4⁺ T, DNT and DPT cells in CD3⁺ T cells isolated 892 from unaffected control and P1 under the stimulation of TS, TSZ and cytokines (combination of IL-1 β 893 (10 ng ml⁻¹), IL-6 (100 ng ml⁻¹), IFN α (100 ng ml⁻¹) and IL-8 (100 ng ml⁻¹)) as indicated for 6 hours. c-894 d, Representative contour plots (c) and summary histogram (d) showing percentages of CD8^{hi} T, CD8^{lo} 895 T, CD4⁺ T, DNT and DPT cells in CD3⁺ T cells isolated from P2 under the stimulation of TS, TSZ, TSN 896 and TSZN as indicated for 6 hours. e, Schematic of CRISPR/Cas9-mediated in situ knock-in of WT 897 *RIPK1* into patients' *RIPK1* locus. **f**, Representative contour plots of Turbo-GFP⁺ cells percentage 898 indicating WT RIPK1 knockin efficiency. g, Statistical analysis of CD8⁺ T cell proportions in CD3⁺ T 899 cells from unaffected controls (n=3-6) and two patients (n=3 for P1 and P2) under the stimulation of TS, 900 TSZ as well as RSL3 (1 μ M) and STS (100 nM) for indicated times. **h**, Representative contour plots 901 showing percentages of CD8⁺ T and CD4⁺ T cells in CD3⁺ T cells isolated from P2 under the stimulation

- 902 of anti-CD3 antibody (5 µg/ml) with or without Ponatinib (250 nM) and Nec-1s (10 µM) for 24 hours. T
- 903 denotes 20 ng ml^1 TNF; S denotes 250 nM SM-164; Z denotes 25 μ M z-VAD-fmk; N denotes 10 μ M
- 904 Nec-1s. Graphs show mean±SD.

906



907

908 Extended Data Fig. 7 | TNF/IFNγ links T-mono axis.

909 a, qRT-PCR analysis of TNF, IL1B and IL6 mRNA levels in GM-CSF-activated monocytes derived

910 macrophages (MDMs) co-cultured with or without T cells for 6 hours. GM-CSF activated MDMs

911 generated from C1 (blank dots) or P1 (red dots) were co-cultured with T cells from unaffected controls 912 (C1 and C2, left panel) or P1 (right panel) as indicated. b-c, Dot plot showing the mRNA expression of 913 IFNGR1, IFNGR2, TNFRSF1A and TNFRSF1B from sc-RNAseq analysis (b) or protein levels of 914 IFNGR1/CD119 and TNFR1/CD120a from CyTOF analysis (c) in cell subtypes found in PBMCs. The 915 size of the circle indicates the percentages of cells positive for gene expression and the color represents 916 the average expression levels. **d**, Representative histograms and statistical analysis of TNF and IFN γ 917 expression in CD4⁺ T cells in PBMCs isolated from unaffected controls (n=6) and patients (n=3 for P1 918 and P2) treated with TS and TSZ for 24 hours. e, T cells stimulated with or without anti-CD3/CD28 919 dynabeads for 24 hours prior to co-culture with MDMs generated from healthy donor 1 (upper panel) or donor 2 (bottom panel) in the presence of 10 µg ml⁻¹ adalimumab, 10 µg ml⁻¹ emapalumab alone or in 920 921 combination for 6 hours. TNF, IL1B and IL6 mRNA levels of MDMs were analyzed by qRT-PCR. f, 922 Working model: RIPK1 activation-dependent CD8⁺ T cell death-triggered inflammatory response of 923 myeloid cells cause SAID. Dots represent each image and graphs show mean±SD.



925



a, Schematic representation depicting conditional human RIPK1 overexpression system in murine HSC
used in this study. b, Representative contour plots showing the bone marrow transplantation efficiency.
c-h, Schematic representation depicting the generation of double transgenic mice used to evaluate the
specificity and efficiency of *Lyz2*-CreERT2 (c) and *Cd8a*-CreERT2 (f). Representative contour plots
showing percentage of GFP⁺ cells in myeloid (d) and T lymphoid lineage(e), as well as in T cell subsets
(g, h) from the whole blood of *Lyz2*-CreERT2::*Rosa26*-mTmG and *Cd8a*::*Rosa26*-mTmG mice with
tamoxifen induction.



936 **Extended Data Fig. 9** | Efficiency of conditionally induced overexpression of RIPK1 in mice.

937 a-d, loxp-GFP-stop-loxp-TagBFP2-P2A-WT/mutated human RIPK1 were lentivirally transduced into 938 HSCs isolated from Lyz2-CreERT2 (a) or Cd8a-CreERT2 donor mice (c). Histogram graphs showing 939 expression levels of GFP in HSCs. Whole blood cells isolated from recipient mice with Lyz2-CreERT2 940 (b) and Cd8a-CreERT2 (d) HSCs transplantation before and after tamoxifen induction. Histogram graphs 941 showing expression levels of TagBFP2 in myeloid cells (b) and $CD8\alpha^+$ T cells (d). e-f, ELISA 942 measurement of serum Tnf and Il-6 levels in mice specifically overexpressing WT or mutated hRIPK1 943 in myeloid cells (e) or CD8 α^+ T cells (f) with 0.5 mg/kg LPS challenge for 2 hours. Statistical significance 944 was determined by two-tailed unpaired t-test.

945



946

947 Extended Data Fig. 10 | CD8 expression in CRIA patients.

a, Sanger sequencing chromatograms of *RIPK1* in whole blood genomic DNA from CRIA patients
(CRIA-1 and CRIA-2). b, Representative contour plots showing percentages of CD4⁺ T and CD8⁺ T cells
in CD3⁺ T cells isolated from CRIA patients. c, Representative contour plots depicting the percentages
of CD4⁺ T, CD8⁺ T, double negative T (DNT) and double positive T (DPT) in CD3⁺ T cells gated from
PBMCs of CRIA-1 culturing *in vitro* for 24 hours. d-g, Contour plots showing the expression of CD8 (d)
or CD4 (f) in CD3⁺ T cells, CD8⁺ (e) and CD4⁺ (g) T cell subsets of four unaffected controls, two patients
(P1 and P2) and two CRIA patients. The protein expression was determined using CyTOF.